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ABSTRACT OF THE DISSERTATION
IDENTIFICATION AND PHENOTYPIC PLASTICITY OF METASTATIC CELLS
IN A MOUSE MODEL OF MELANOMA
by
Xiaoshuang Li
Florida International University, 2017
Miami, Florida
Professor Lidia Kos, Major Professor
Melanoma is the deadliest form of skin cancer due to its high propensity
to metastasize and resistance to current therapies. We have created a
spontaneous mouse model of metastatic melanoma (Dct-Grm1/K5-Edn3)
where metastasis to the lungs is 80% penetrant. The primary tumors of these
mice present cellular heterogeneity with cells at varying levels of differentiation.
The main goal of this study was to determine the metastatic potential of the
primary tumor resident Tyrosinase positive cells and evaluate the dynamic
phenotypic changes as those cells move from the primary tumors to the sites of
metastasis. To accomplish this aim I crossed the Dct-Grm1/K5-Edn3 mice to
CreERT2/mT/mG mice to indelibly label Tyrosinase cell populations within the
primary tumor with Green Fluorescent Protein (GFP) by topical application of 4hydroxytamoxifen (4HT) at the tumor site. In vivo lineage tracing and
characterization of GFP+ cells were performed in the metastatic lesions.
In the 4HT treated Dct-Grm1/ K5-Edn3/Tyr-CreERT2/mT/mG mice,
primary tumor derived Tyrosinase positive cells or their progeny (GFP+)
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established successful metastases in the distant organs indicating the
tumorigenic capacity of the differentiated cell populations. Numerous metastatic
melanoma cells were identified in the vasculature of the metastatic organs and
established close association with the vascular endothelium. The intravascular
cells lost pigmentation and did not express melanocytic markers; however, they
mimicked endothelial cell properties and gained the expression of CD31 (also
known as platelet endothelial cell adhesion molecule PECAM-1) and vascular
endothelial (VE)-Cadherin. In the lung metastatic foci, GFP+ cells resumed
pigmentation production and lost the expression of endothelial cell markers.
Evidence from other metastatic organs in the mice further supported the
phenotypic plasticity of metastatic melanoma cells.
The in vivo lineage tracing system established in the melanoma mouse
model revealed tumor phenotypic plasticity and will be a powerful model to
evaluate and help us understand the etiology and pathogenesis of melanoma
metastasis. Further characterization of those more aggressive cells in
melanoma will allow for the development of new prognostic tests and novel
therapeutic strategies to eliminate metastasis.
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CHAPTER
1.

INTRODUCTION
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1.1 Introduction
Most cancer patients die of metastasis [1]. Cancer metastasis is the
spread of a cancer from one organ or part of the body to another organ or part of
the body that is not directly connected. The process of metastasis consists of a
series of interconnected, sequential or parallel steps that must be completed by
tumor cells if a metastasis is to develop, although the exact steps for individual
tumors are widely context-dependent. The vasculature plays essential roles
during cancer metastasis. In addition to the authentic endothelial cell-lined
vasculature, new models of vasculature, such as vasculogenic mimicry, vessel
co-option and cancer cell-derived endothelial cells, have been reported [2].
Mechanisms underlying tumor metastasis are still under investigation, among
which epithelial-mesenchymal transition (EMT) is receiving increasing attention
[3, 4].
Melanoma is the type of skin cancer that causes the most deaths because
of its high metastatic potential. Progression of normal melanocytes to metastatic
melanoma was thought to be linear, but recent evidence has suggested it is more
complex and less linear in nature [5]. Clinical cases of late recurrence after the
initial primary melanoma resection [6] not only implicated the early dissemination
of tumor cells, but also suggested melanoma dormancy. Although a number of
studies have proposed an important role for cancer stem cells (CSCs) in
melanoma, their existence and relevance remain a controversial issue [7]. The
role of circulating tumor cells (CTCs) in metastatic colonization is also extensively
discussed [8, 9]. In this chapter, steps of cancer metastasis are summarized and
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the putative roles of EMT in metastasis are reviewed. In addition, descriptions of
melanoma progression and dormancy are introduced as well as the current
available evidence for metastasis-initiating cells focusing on CTCs.
1.2 Cancer Metastasis
1.2.1 Steps in Metastasis
Cancer metastasis involves several steps; metastatic cancer cells leave
the primary tumor, travel to distant organs through various mechanisms and
eventually seed

metastases in

the

secondary organs. Blood/lymphatic

vasculature plays essential roles in cancer metastasis by providing a route for the
travel of cancer cells from primary sites to secondary sites. As malignant cancer
cells start to proliferate out of control, a solid mass will appear as the primary
tumor. Further growth of the primary tumor was originally believed to be
angiogenesis-dependent and neovascularization was needed for tumor invasion
and metastasis [10]. The promise of this hypothesis has been subjected to
clinical evaluations and anti-angiogenesis agents have been used as standardof-care therapies for various types of cancers [11]. Later, this classic concept
was challenged by studies showing that micro-tumors may initiate tumor growth
by hijacking the pre-existing host vessels, a process known as vessel co-option
(also known as vascular co-option), without inducing angiogenesis in a
vascularized tissue [12-15]. Vessel co-option is also responsible for tumor
progression after anti-angiogenesis therapies [16-19]. Other than the endothelial
cell-lined vasculature in tumors, aggressive tumor cells can form blood-perfused
tubular channels, termed as vasculogenic mimicry (VM), linking directly to normal
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vessels for the blood supply of the tumor growth [20]. Although aggressive uveal
melanoma cells engaged in the formation of VM in 3D Matrigel downregulated
invasiveness related genes [21], VM is strongly associated with clinical deaths of
metastasis in uveal and cutaneous melanoma patients [22, 23]. The plasticity of
tumor cells to gain an endothelial-like phenotype is depicted in another form of
vasculature in cancer, the mosaic vessels. Tumor cells can mimic endothelial
cells by participating in the formation of blood vessels. Mosaic vessels are
marked by discontinued endothelial cell marker CD31 expression and the
replacement of some endothelial cells with tumor cells in the vessels [24]. It is
reasonable to propose that the presence of cancer cells within the mosaic
vessels in contact with the blood lumen indicate tumor dissemination and
metastasis [25]. Recent observations in glioma adds another layer to the role
played by the tumor vasculature in that glioma cells can transdifferentiate into
endothelial cells and express endothelial cell markers [26-31].
Several interactions or phenomena between cancer cells and the
vasculature have been suggested or observed. The well-studied interaction
between cancer cells and blood vessels is transendothelial migration. Tumor
cells can migrate through the vascular endothelium to reach the blood
(intravasation) and after transport in the blood stream, some cells can get out of
the vasculature (extravasation) to seed metastases. Tumor cells within the blood
stream are called circulating tumor cells (CTCs). Metastatic tumor cells can enter
circulation as single cells or as cell clusters [32]. Circulating tumor cells have
been successfully isolated from human blood in several cancers [33-36]. During
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hematogenous dissemination, intravascular rolling behavior of metastatic cancer
cells has been reported [37-41]. In contrast to intravascular dissemination or
migration, Lugassy and Barnhill suggested “angiotropism” in melanoma as a new
mechanism of tumor spread. They termed this phenomenon as 'extravascular
migratory metastasis' (EVMM), emphasizing the pericytic mimicry of tumor cells.
Extravascular migratory metastasis describes the continuous migration of tumor
cells along the abluminal vascular surfaces to nearby or more distant sites [4244]. The similarity of vessel co-option and angiotropism and the significance of
these mechanisms during the metastatic process have been further discussed in
a brain melanoma mouse model [15].
At the metastatic sites, tumor cells reach the metastatic organs by
whichever migration mechanism (extravasation, vessel co-option, EMVV) and
start to proliferate and seed successful metastases. Intravascular proliferation of
tumor cells has been suggested as an alternative origin of early metastasis in the
lung [40, 45]. Instead of angiogenesis switch for further growth of metastatic
tumors, vessel co-option is common in vasculature-rich tissues [18]. The overall
process of cancer metastasis is summarized in Figure. 1.1.
1.2.2 Mechanisms underlying Metastasis
1.2.2.1 Epithelial-mesenchymal transition
Epithelial-mesenchymal transition was originally defined in developmental
biology as a conversion from embryonic epithelia to individual mesenchymal cells
that can invade and migrate through the extracellular matrix (ECM) [46]. During
normal development, epithelial cells provide cell-cell adhesion essential to
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establish a barrier to the external environment for the development of embryos.
In contrast, mesenchymal cells are free to rearrange or move around in three
dimensions thus adding more plasticity for body patterning and morphogenesis
[47]. Epithelial-mesenchymal transition involves not only morphological changes
but also gene expression switch, in particular, the downregulation of E-cadherin
and upregulation of N-cadherin. It took a long time for EMT to be recognized as a
potential mechanism underlying carcinoma progression. Since local invasion is
the first step for cancer metastasis, it is essential for tumor cells to lose cell-cell
adhesion and acquire invasive or migratory behaviors. The similarities between
the tumor malignancy switch and the developmental signature have solidified the
notion that EMT is a major contributor to the escape of tumor cells from the
primary tumors [48].
Although clinically carcinomas (tumors of epithelial origin) and sarcomas
(tumors of mesenchymal origin) are generally not thought to interconvert, various
carcinoma cell lines undergo EMT during specific culturing conditions in vitro [49].
The first evidence of EMT in cancer was noted by studies demonstrating that
invasiveness and adoption of a fibroblast morphology can be achieved by down
regulation of E-cadherin expression in various epithelial cancer cell lines [50, 51].
In addition, re-expression of E-cadherin can reverse the invasive property of
cancer cells [50, 52, 53]. Transforming growth factor-beta (TGF-) was shown to
be a main inducer in the cancer EMT process. Transformed mammary epithelial
cells exhibited fibroblastoid properties in the presence of TGF-, the converted
cells themselves produced high levels of TGF-1 and maintained a highly
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invasive phenotype both in vitro and in vivo. Neutralization of TGF- reverted the
epithelial phenotype of the fibroblastoid cells [54]. Blockage of TGF- receptor
abolished metastasis formation in highly metastatic mesenchymal mouse colon
carcinoma cells [55]. However, because of the numerous biological interactions
TGF- is involved in, the interpretation that EMT occurs in response to TGF- is
complex [56]. The understanding of EMT in cancer advanced when specific
transcriptional modulators of E-cadherin gene promoter were identified. In 2000,
two groups showed strong evidence that Snail1 binds directly to the promoter of
E-cadherin and represses the transcription of this gene in invasive mouse and
human carcinoma cell lines [57, 58]. Other Zn (zinc)-finger transcription factors,
including Snail2 [59], ZEB1 [60], ZEB2 [61], were also shown to directly bind to
the E-boxes of the E-cadherin promoter to repress its transcription. In addition to
these Zn-finger transcription factors, ectopic expression of bHLH family
transcription factor Twist1 resulted in the loss of E-cadherin mediated cell-cell
adhesion, expression of mesenchymal markers and induction of cell motility,
hallmarks of EMT in normal mammalian cells. Suppression of Twist in highly
metastatic mammary carcinoma cells inhibited their metastatic capacity from the
mammary gland to the lung in a murine breast tumor model [62]. Correlations
between Twist1 and Snail2 during EMT in cancer metastasis were also
discussed [63]. Other signaling pathways underlying EMT include bone
morphogenetic protein (BMP), Wnt–β-catenin, Notch signaling, Hedgehog
signaling, and receptor tyrosine kinases. In addition, environmental factors such
as hypoxia and ECM also contribute to EMT process [64, 65].
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Nonetheless, the abundant stromal fibroblasts and the dynamics of EMT
challenge our interpretation of EMT in human tumors [4]. Although numerous
clinical studies correlate EMT with poor clinical outcomes, direct evidence is
better demonstrated from the studies of CTCs. By lineage tracing, epithelialorigin CTCs acquiring EMT phenotype were identified in a mouse model of
pancreatic cancer [66]. Another study, using a spontaneous squamous cell
carcinoma mouse model, showed that activation of EMT by Twist1 induction
increased CTCs over 2-fold compared with the control group, most important,
these CTCs exhibited mesenchymal marker expression [67]. In a human breast
cancer xenograft mouse model, Bonnomet et al. showed that EMT in the primary
tumor was associated with an enhanced number of CTCs that expressed
mesenchymal markers Snail, Slug and Vimentin [68]. Circulating tumor cells with
an EMT feature have also been reported in human patients, including breast
cancer, lung, colorectal, prostate, bladder, ovarian, and endometrial cancers [6971].
1.2.2.2 EMT and Stemness
Cancer stem cells (CSCs), also known as cancer-initiating cells, are those
cells that have the ability to perpetuate themselves through self-renewal and to
generate mature cells of a particular tissue through differentiation [72]. Cancer
stem cells share similar stemness as regular stem cells in developmental
processes. Recent studies have correlated EMT with stemness or CSCs. Mani
and colleagues showed immortalized human mammary epithelial cells acquired
the expression of stem-cell markers after EMT induction, and those transformed
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cells exhibited stem-cell properties by a higher efficiency in mammosphere and
tumor formation [73]. In the context of cancer metastasis, the relationship
between EMT and tumor-initiating capacity is better identified by studies on
CTCs. Circulating tumor cells isolated from breast cancer patients showed EMT
and stem cell characteristics, and inclusion of EMT markers to optimize CTCs
detection was suggested [74-76]. In another study, a cell subpopulation with both
tumor-initiating feature (CD44+/CD24−/low) and in vitro mammosphere-forming
potential was identified in conventional therapy treated breast cancer samples.
The increased expression of mesenchymal markers in this cell subpopulation has
related EMT with tumor-initiating cells [77]. In a study of epithelial lineage tracing
in a mouse model of pancreatic cancer, the authors showed that epithelialderived CTCs expressed mesenchymal markers, and further characterized the
tumor initiating properties of those cells by transplantation [66]. However, not all
cells that have undergone EMT possess stem cell-like properties, as is shown by
the study in a spontaneous model of EMT using a primary prostate cancer
derived cell line [78]. The cross talk between EMT and stemness is far more
complex than expected. Different research groups have demonstrated that EMT
can suppress the tumor-initiating capacities of human epithelial cells [79].
Epithelial-mesenchymal transition and stemness may be coupled, antagonistic or
independent processes in cancer metastasis [80].
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1.3 Melanoma Skin Cancer
1.3.1 Melanoma Progression
Cutaneous melanoma has been one of the fastest rising cancers over the
past several decades. According to the American Cancer Society, about 87,110
new melanomas will be diagnosed and 9,730 people are expected to die of
melanoma in 2017. Melanoma is notorious for its tendency to metastasize and
for its poor response to current therapeutic regimens.
Melanoma results from the malignant proliferation of melanocytes, the
pigment producing cells in the skin. The classic paradigm describing the
progression of normal melanocytes to metastatic melanoma is linear [81, 82].
Melanoma starts from the melanocytic nevus, a benign precursor lesion, followed
by the dysplastic nevus. The first malignant stage of melanoma is called the
radial growth phase (RGP). At RGP, transformed melanocytes start to spread
laterally, but remain close to the epidermis and still under the control of the
growth factors from the keratinocytes. The continuing invasion of melanocytes
from basement membrane to the upper epidermis and lower dermis leads to the
next stage, vertical growth phase (VGP). At VGP, melanocytes completely
escape from the keratinocyte signals and new interactions between surrounding
stroma cells are established. Melanocytes at VGP have the potential to
disseminate and seed distant metastases in other organs [81-83].
However, the progression of melanoma may not be sequential or linear;
emerging evidence both in mouse models and clinical observations suggest a
much more elaborate view of melanoma metastasis [5]. In contrast to the
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traditional notion that metastasis is a late event in tumor progression and it only
occurs after the completion of all the required stages, early dissemination of
abnormal cells was detected in both murine models and human samples.
Husemann performed a comprehensive study about the early dissemination of
breast cancer cells in both HER-2 and PyMT transgenic mice. In these breast
cancer mouse models, transformed epithelial cells disseminated early from the
atypical hyperplastic areas and those early disseminating cells can grow into
metastases. Another finding of this study is that the dissemination of tumor cells
was not associated with tumor size both in the mouse model and ductal
carcinomas in situ in women [84]. A similar study using PyMT mice identified the
stem cell property of some early disseminating cells. The disseminating and
tumorigenic potential of the disseminating cells was further assessed by
transplantation assay using GFP PyMT mice [85]. In a study by Podsypanina et
al., untransformed mouse mammary cells in circulation were able to acquire
malignant growth upon oncogene activation. They demonstrated this by
introducing the premalignant mammary cells into circulation directly without going
through the transformation within the primary tumors. Although they could not
show the timing of the dissemination, they argued the possibility that
untransformed cells that disseminated early could account for the later
metastases [86]. Early dissemination before tumor formation was also reported in
a pancreatic tumor mouse model, in which cells disseminated at premalignant
stage reached the liver as single cells albeit no micro- or macro-metastases were
observed [66]. In the spontaneous melanoma mouse model RET.AAD, early
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dissemination of melanoma cells before primary tumor formation was identified
through a series of assays, including SNP genetic analysis, IHC, RT-PCR and
H&E staining. The authors also noted the dormancy of disseminating tumor cells
in the lung [87]. Clinically, numerous cases of patients with metastatic melanoma
free of detectable primary tumors have been reported [88-93].
1.3.2 Melanoma Dormancy
Malignant melanoma is one of the two malignancies with the highest
donor tumor transmission rates (74% transmission rate with 58% mortality) in
human transplantations [94]. Organs from donors with melanoma history but free
of disease for more than 10 years after initial surgery can present with recurrent
metastasis in organ recipients. Late recurrence of melanoma after the initial
primary tumor resection is reported [6]. Although various adjuvant therapies are
designed to prevent the development of local recurrences or metastasis by
targeting “residual” disease, the results have not necessarily been successful.
Why is it that the “residual” tumor cells are so persistent? The answer may lie in
the fact that the biology of some “residual” cells, that may disseminate into other
organs before the removal of primary tumors, seem to be highly divergent from
that of the primary tumor and/or overt metastasis [95]. All clinical observations
listed previously point to an increasing concern surrounding melanomametastatic dormancy, which may be the underlying cause for the incomplete cure
of melanoma.
Although a handful of reviews on melanoma dormancy are available [9698], the number of studies specifically focusing on this phenomenon in

12

melanoma is very limited compared with that for breast and prostate cancers.
Despite the well documented clinical observations, evidence of melanoma
dormancy in mouse models, which could serve as a useful tool to reveal the
mechanisms underlying human disease, is scarce. An early study by Cameron et
al. showed dormancy of solitary melanoma cells in lung using B16F10 cell
injection. They concluded that solitary cell dormancy is a post-extravasation
event contributing to metastasis inefficiency [99]. A similar study, where human
melanoma cells were injected into the tail vein of immunodeficient mice,
demonstrated that single or clusters of <10 cells in the lung failed to proliferate in
vivo up to 60 days but retained tumor initiating capacity after in vitro culture [100].
Another study employing in vivo imaging showed that uveal melanoma cells can
persist in the liver for 6 weeks in a dormant state [101]. Nonetheless, these
studies did not provide or propose the underlying mechanisms for how these
cells kept dormant and were able to escape immune attack in the metastatic
organs. Without a mechanistic understanding, the evidence of melanoma
dormancy in humans or mice is of little use in reducing recurrence or increasing
survival of patients. A very recent study by Touil et al. may offer more clues on
melanoma dormancy. In their study, they obtained a mouse model of melanoma
dormancy through melanoma-based immunotherapy and ascertained the in vivo
existence of immune-resistant dormant melanoma cells in different organs by
qRT-PCR one year after the immunotherapy challenge. Unfortunately, no spatial
information
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cells

was

reported

and

the

following

characterization of the dormant cells was done through in vitro study of the
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dormant cell-derived cell lines. Although they provided evidence that the dormant
cells presented stem-like properties and that the GILZ/FOXO3A pathway was
involved in the quiescence of those cells, these in vitro results are not as
convincing as in vivo characterization [102].
1.3.3 Melanoma and Metastasis-Initiating Cells
Melanoma is less common, but more serious than other types of skin
cancers because of its high metastatic potential. The cellular composition of
tumors is heterogeneous; there are many subpopulations of cells within the same
tumor. Some cells are more differentiated, some are less differentiated showing a
stem cell-like phenotype. Recent evidence suggested that the less differentiated
cell population (i.e.,CSCs) may be responsible for tumor initiation and resistance
to therapies [72]. Although several melanoma stem cell markers have been
described [103-107], the robustness of these markers is questionable
considering the limitations of the xenotransplantation assay that is widely used in
cancer stem cell studies. In addition, the tumor initiating capacity of CSCs in
melanoma was mainly discussed in the context of primary tumor formation and
little is known about metastasis-initiating capacities. The differentiation levels of
melanocytes with respect to their ability to metastasize was discussed by
Damsky et al. Microphthalmia-associated transcription factor (MITF) and WNT/ catenin signaling are the known players controlling melanocyte differentiation, but
their effects on melanoma metastasis seem to be context-dependent. Two
hypotheses have been proposed to explain the controversial effects of the two
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players on metastasis: the proper balance in the degree of differentiation, and the
phenotypic plasticity of melanoma cells [5].
If during metastasis, the dissemination of tumor-initiating cells is required,
presence of circulating tumor-initiating cells should be associated with worse
patient outcome. A study demonstrated that CD133 and Nestin were expressed
on CTCs, and those CTCs showed a similar expression profile with the matched
metastatic lesions [108]. Another corroborating study demonstrated that Nestin
was expressed in a proportion of melanoma cells enriched from peripheral blood
of melanoma patients, and the expression level of Nestin was higher in stage IV
patients compared with stage III ⁄ IV patients [109]. Clonal dominance of CD133
in primary tumors of patients with recurrence or metastatic lesions was found,
suggesting that CD133 subpopulation may be a determinant of tumor
metastasis/tumor relapse [105]. Another study using experimental metastasis
models, showed that the WNT receptor, FZD7, was required for the initiation and
proliferation of metastatic melanoma growth [110]. In addition, Frank’s group has
identified a subpopulation of tumor-initiating cells in melanoma by ABCB5
expression [111]. Later they showed that human melanoma CTCs contain
tumorigenic

cell

subpopulations

capable

of

causing

metastases,

most

interestingly, ABCB5-positive tumor cells were highly enriched among melanoma
CTCs compared to either primary tumors or pulmonary metastases [112].
1.4 Research Questions
Although efforts to identify melanoma-initiating cells (MICs) or CSCs are
increasing and strong evidence is emerging, connections between MICs and
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metastasis still remain an open question. This is partly because of the complexity
of tumor progression in that both external and internal factors may account for
tumor metastasis. Another reason is the lack of good melanoma metastasis
models. For obvious reasons, it is impossible to follow a specific cell population
in human melanoma patients from the primary tumor to the metastatic sites to
check their metastasis-initiating capacity. Proper mouse melanoma metastasis
models are very limited and in vivo tracing of cells requires numerous optimized
conditions, such as timing of metastasis formation and visualization of interested
melanoma cells. The effort to fully characterize melanoma metastasis-initiating
cells is worthwhile because it will not only enhance our understanding of
melanoma metastasis, but also provide insights for the development of
metastasis-targeted therapies.
Phenotypic plasticity of cancer cells is a well-recognized phenomenon; we
know that tumor cells can switch gene expression profiles as necessary to best
adapt to the environment. However, to what extent and how these changes are
related to the spatial or temporal dimensions of tumor progression have not been
sufficiently investigated. Histological and morphological dynamics may be
observable through real-time in vivo imaging on zebrafish models or mouse
models for a short period, while genetic changes are hard to be characterized in
those setups. A detailed lineage tracing study in melanoma has not been
pursued. As such, the establishment of an in vivo lineage tracing system of the
tumorigenic cell subpopulations in a spontaneous mouse model of melanoma
metastasis is essential. This system will not only delineate the tumor-initiating
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capacity of specific cell subpopulations in the context of metastasis but also
indicate the phenotypic plasticity of the metastatic cells (Figure 1.2). My overall
hypothesis is that the primary tumor derived cell subpopulation with a more
differentiated state possesses metastasis-initiating capacities and exhibit
phenotypic plasticity during the metastatic process. To test this hypothesis, I
addressed the following questions:
Question 1: Can primary tumor derived cell subpopulations with a more
differentiated state reach the secondary organs and seed successful
metastases?
I created a spontaneous melanoma metastasis mouse Tg (Grm1) Epv /
K5-tTA-Edn3 (referred to as Dct-Grm1/ K5-Edn3) where metastasis to the lungs
is 80% penetrant. Using the Cre/loxp system, I genetically labeled Tyr expressing
cell subpopulations within the primary tumors with GFP in these mice and
performed lineage tracing of the labeled cells. I hypothesized that the primary
tumor derived Tyr expressing cells or their progeny can reach the lung and
successfully seed metastases indicating the tumor-initiating capacities of the
differentiated melanoma cell subpopulation.
Question 2: When do the metastatic melanoma cells start to disseminate
into the circulation system?
My aim was to identify the metastasis-initiating capacities of the primary
tumor derived Tyr expressing cells. Experimental mice were monitored for
several months after primary tumor formation. Given the variability in the timing
of primary tumor and lung metastasis formation, I could not establish the exact
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time of arrival of metastatic cells in the lung. Instead, I focused on the timing of
metastatic cell intravasation. I labeled Tyr expressing cells in the mice at three
different stages during tumor progression: pre-nevus stage, nevus stage and
mature tumor stage. I hypothesized that Tyr expressing cells can invade blood
vessels even before the appearance of any noticeable nevus.
Question 3: What are the phenotypic changes that cells undergo during the
process of metastasis?
The GFP+ metastatic cells are derived from Tyr expressing cells inside the
primary tumors. As the cells leave the primary tumors and enter the circulatory
system, I hypothesized that the gene expression profile and pigmentation levels
of those cells may undergo a reversible switch to facilitate metastasis. I used
immunofluorescence staining with various markers to characterize the phenotype
of metastatic cells associated with the pulmonary vasculature.
Question 4: What are the putative mechanisms underlying melanoma
metastasis?
The GFP+ cells found in the lung were mostly associated with the vascular
endothelium with an elongated shape. The mechanism and functional
significance underlying the association between metastatic melanoma cells and
vascular endothelial cells is not clear. I performed immunofluorescence staining
of intravascular metastatic melanoma cells with endothelial cell specific markers
and hypothesized that melanoma-endothelial transition in the primary tumors and
endothelial-mesenchymal transition

(EndMT)

in

the

metastatic site

are

mechanisms underlying melanoma metastasis in the Dct-Grm1/K5-Edn3 mice.
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Figure 1.1 Diagram of cancer metastasis.
In primary tumors, angiogenesis, vessel co-option, VM and mosaic vessels are
potential mechanisms underlying tumor vasculature. The vasculature in primary
tumors not only provides oxygen and nutrients for tumor growth, but also
provides a potential route for tumor dissemination. Metastatic tumor cells enter
the circulation system as single CTCs or clusters through intravasation or other
dissemination pathways or migrate along the abluminal vascular surfaces to
nearby or distant sites as EVMM. CTCs arrest at the vascular endothelium in the
metastatic organs and establish interactions with endothelial cells, roll along the
endothelium to find the best sites for extravasation. Extravasated tumor cells
proliferate and grow using angiogenesis or vessel co-option. EVMM is another
potential source for metastases formation. Intravascular growth of metastatic
cells in the microvessels with subsequent extravasation when intravascular
micro-metastatic foci outgrow the vessels they are in can be another source.
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Figure 1.2 Identification of metastatic cell populations in melanoma.
Cells with varying differentiation levels are indicated by different colors in melanoma primary tumors. Certain
melanoma cells can leave the primary tumor, enter the circulation system and reach the distal organs to seed
metastases. The cell subpopulations that initiate melanoma distant metastases are still unclear and the phenotypic
plasticity of the metastatic cell populations will be under investigation.
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CHAPTER
2.
LINEAGE TRACING AND CHARACTERIZATION OF THE
METASTATIC CELL POPULATION IN A MOUSE MODEL OF MELANOMA
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2.1 Introduction
Tumors are heterogeneous, involving not only the differences between
various solid tumors but also between cell subpopulations within the same tumor.
One of the important aspects of tumor heterogeneity that has recently gained
increasing acceptance is the cancer stem cell model [1-3]. When it was first
introduced in studies of human myeloid leukemia, it proposed that tumors are
comprised of phenotypically diverse populations of cells, with only a rare,
phenotypically distinct subset of cells having the capacity to significantly
proliferate and form new tumors, while the bulk of cells within the tumor lose the
tumorigenic capacity [4]. The cancer stem cell hypothesis has been extended to
a great array of solid tumors. Using a model in which human breast cancer cells
were grown in immunocompromised mice, Al-Hajj et al. showed that only a
minority of breast cancer cells possessed the ability to form new tumors. Using
the cell surface markers CD44+CD24−/low expression, they were able to
distinguish the tumorigenic from the non-tumorigenic cancer cells within the
breast cancer bulk [5]. Later, Singh et al. demonstrated that only the CD133+
brain tumor fraction contained cells capable of tumor initiation in NOD-SCID
mouse brains and injection of as few as 100 CD133+ cells produced a tumor that
could be serially transplanted and re-establish the heterogeneity of the parental
tumor, whereas injection of 105 CD133- cells did not produce a tumor [6]. A
similar study was carried out on prostate cancer. On the basis of the high surface
expression of integrin 21 and CD133, the authors reported the identification
and characterization of a subset of cells from primary and metastatic prostate
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tumors that had cancer stem cell characteristics, which was also able to
regenerate the phenotypically mixed populations of nonclonogenic cells [7]. In a
study of human colorectal cancer, O’Brien et al. identified a human coloninitiating cell subpopulation that was able to maintain themselves as well as
differentiate and reestablish tumor heterogeneity upon serial transplantation
using CD133 expression [8]. Subsequently, Dalerba et al. provided a more
extensive surface marker profile, which better supported the tumor heterogeneity
hypothesis, highlighting the epithelial cell adhesion molecule (EpCAM), also
known as epithelial-specific antigen (ESA), and CD44 as more robust markers for
colorectal cancer stem cells when compared to the previously reported marker
CD133 [9]. Another study using a xenograft model identified a highly tumorigenic
subpopulation of pancreatic cancer cells expressing the cell surface markers
CD44, CD24, and ESA [10]. Using a similar approach as that for studies on
breast cancer, Prince et al. identified a subpopulation of cells with cancer stem
cell properties in head and neck squamous cell carcinoma (HNSSC), which were
CD44+ and typically comprised <10% of the cells in a HNSCC tumor [11].
The cancer stem cell model has also been proposed for melanoma [12]
and several melanoma stem cell markers such as Nestin [13], CD133 [14, 15],
CD271(also p75NTR) [16, 17], and JARID1B [18, 19] were demonstrated to
select a subpopulation of melanoma cells with a higher tumor initiating capacity.
However, the cancer stem cell model remains controversial in the melanoma field
and several questions are still unanswered. For example, are the cancer stem
cells a constant cell population within the hierarchically organized tumor? Or
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does reversible phenotypic plasticity exist among these markers? Quintana et al.
[20] pointed out that the frequency of tumorigenic melanoma cells that can be
detected after xenotransplantation was highly assay-dependent. By making a
series of changes in assay conditions, they increased the detectable frequency of
tumorigenic melanoma cells after xenotransplantation into NOD/SCID IL2Rgnull
(NSG) mice, proving that both CD133+ and CD133- fractions formed tumors that
exhibited similar heterogeneity in CD133 expression. In a subsequent study [21]
by the same group, neither ABCB5 nor CD271 expression defined a
subpopulation of cells that had enriched tumorigenic potential since all injections
formed tumors that were phenotypically similar to the parent tumors irrespective
of whether the cells injected were marker positive or negative. Additionally, both
CD271+ and CD271- cells formed tumors capable of metastasis. Combined, the
results of Quintana et al. led them to the conclusion that tumorigenic cells
appeared to undergo reversible changes in the expression of many markers in
vivo. This conclusion is further supported by the study of Roesch et al. [19]
demonstrating that the JARID1B phenotype was dynamic, in that JARID1Bnegative cells also gave rise to a heterogeneous progeny containing JARID1Bpositive cells, which suggested a new understanding of melanoma heterogeneity
with tumor maintenance as a dynamic process mediated by a temporarily distinct
subpopulation.
Overall, the two key components in the cancer stem cell scenario, the
rarity and tumor initiating capacity, are still being questioned [22-24].
Xenotransplantation experiments were the basis to enrich tumorigenic cells from
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non-tumorigenic cells in most of the cancer stem cell studies. Though widely
used, as human tumor cells are being processed and transplanted, they are
subjected to new environmental conditions that may alter their phenotype and
consequently their tumor initiating capabilities [25]. Any of the conditions, such as
the enzymatic dissociation conditions for human cells, mouse injection sites, the
use of immunocompromised mice, as well as the patient’s stage of disease can
contribute to conflicting results. Civenni et al. [16] developed a protocol to avoid
trypsin during melanoma cell fraction preparation and the results obtained were
compatible with those of some earlier studies. Their study provided some more
convincing data given that the injected cells most likely did not lose surface
marker expression because of interactions with digestive enzymes. Roesch et al.
[19] compared the different effects of cell culture conditions and found that
human embryonic stem cell medium better supported the survival of cells with
inherent self-renewal potential when compared with conventional culture
conditions. The optimized xenotransplantation assay with a more highly
immunocompromised NOD/SCID IL2Rγnull mice

increased the detection of

tumorigenic melanoma cells, demonstrating that tumorigenic cells are common in
some human cancers [20]. Furthermore, certain cancer cell subpopulations were
shown to have reversible drug-tolerance capacity and lose their stem cell
markers during this process [26]. It is thus reasonable to speculate that the
injection of cells obtained from patients that have undergone particular medical
treatments may result in the generation of stem cell marker negative cells with
tumorigenic capacity.
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Because of the complexity of the metastatic process and the conflicting
results obtained from injection and xenotransplantation studies, I propose that
the direct in vivo lineage tracing of tumorigenic cells in a spontaneous mouse
model of melanoma is a more robust and powerful tool to understand how
specific subpopulations of cells within a tumor acquire highly invasive properties
and is responsible for the seeding of distant lesions. My study will provide
significant value to the understanding of melanoma metastasis and offer new
venues for therapy development of melanoma patients.
The use of lineage tracing in the cancer field has become more popular in
recent years emphasizing the tracing of all progeny of one single cell. The basic
foundations of lineage tracing and how data obtained from lineage tracing can be
interpreted is reviewed by Blanpain and Simons with the focus on epithelial
tissues [27]. Lineage tracing by genetic labeling is widely used for cell fate
determination of stem and progenitor cells in the field of developmental biology,
tissue maintenance and repair, and dynamics of tumor initiating capability of
cancer cells. Shin and colleagues did fate mapping of Sonic hedhehog (Shh)
expressing basal cells of the urothelium by lineage tracing and showed that Shh
expressing cells can function as stem cells capable of generating all cell types to
help maintain the epithelial integrity upon bacterial infection or chemical injury
[28]. Another epithelial stem cell lineage tracing study performed in the murine
small intestine showed that B lymphoma Mo-MLV insertion region 1 homolog
(Bmi1)-expressing cells act as an alternative stem cell pool after the ablation of
Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) expressing
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stem cells [29]. In vivo lineage tracing and retracing by multicolor reporter mice
gave the first strong evidence that Lgr5 expressing cells are stem cells in
unperturbed primary tumors on a mouse model of intestinal adenomas [30]. A
more recent clonal analysis using multicolor lineage tracing system on intestinal
tumors further demonstrated the cancer stem cell role of Bmi1 and Lgr5
expressing cells during tumor propagation [31]. Another good example for
lineage tracing was carried out by Zhu and colleagues on high grade brain
tumors [32]. This study gave direct evidence that Tlx is a brain tumor stem cell
marker in a mouse model using RCAS/tv-a system [33] for tumor induction and
Cre/loxp system for in vivo lineage tracing. Although lineage tracing has been
widely used in different fields and certain kinds of tumors, there is a substantial
gap in the field of melanoma biology and little is known about the cellular origin of
melanoma, especially in identification of the precursor cells of metastasis. This is
most likely the result of the lack of a good metastatic melanoma mouse model
that can be used together with Cre/loxp system. In contrast, lineage tracing of
stromal or endothelial cells during melanoma formation is easier since melanoma
tumors can be obtained through tumor engraftment and transgenic mice with
stromal or endothelial cells labeled are available. A recent quantitative clonal
analysis using multicolor lineage tracing by Corey et.al [34] showed that in an
elaborate tumor microenvironment created by the injection of the murine
melanoma cell line B16F10, blood vessels followed a pattern of dynamic clonal
evolution accompanied by the loss of lymphocyte adhesion molecules favoring
the immune escape of cancer cells. The establishment of an in vivo lineage
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tracing system to provide a detailed characterization of the cellular origin of
melanoma metastasis is needed and will be of great significance both to the field
of basic cancer research as well as to future clinical applications.
2.2 Results
2.2.1 Tumor Heterogeneity Exists in Mouse Melanoma
To demonstrate cellular tumor heterogeneity in mouse melanoma, I
studied the composition of tumors from Hepatocyte Growth Factor/Scatter Factor
(HGF/SF) mice [35], Dct-Grm1/ K5-Edn3 mice and Dct-Grm1/K5-Edn3/Dct-Ednrb
mice with spontaneously developed or UV induced lesions. Nestin [13], CD 271
(also known as p75) [16, 17] were chosen as the stem cell markers and
tyrosinase (TYR) or tyrosinase related protein 1 (TRP1) were used as
differentiation cell markers. All the three melanoma tumors showed cellular
heterogeneity with non-overlapping cell subpopulations positive for various
markers (Figure 2.1).
2.2.2 Mouse Model and Methodology Validation
The Dct-Grm1/ K5-Edn3 mice were created in our laboratory [36, 37].
Depending on the aberrant expression of glutamate metabotropic receptor 1 in
melanocytes and environmental Endothelin 3 (Edn3) expressed by keratinocytes,
these mice not only spontaneously develop melanoma tumors on the ear, tail and
dorsal skin, but also show metastases in the lung (Figure 2.2).

Chin et al.

previously showed that Edn3 signaling promotes melanoma progression in DctGrm1/ K5-Edn3 mice resulting in 80% penetrant lung metastases compared with
the Dct-Grm1 controls that have limited metastatic capability [38]. On the basis of
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the tumor heterogeneity scenario, this spontaneous mouse model of melanoma
metastasis will be an ideal system to identify the intrinsic tumor initiating capacity
of certain cell subpopulations within an unperturbed tumor environment. Given
that the Nestin positive melanoma stem cells are rare in these tumors (Figure
2.1), the differentiated Tyr expressing cells which constitute the majority of the
tumor is a better option for lineage tracing. Tyrosinase is a copper-containing
enzyme that catalyzes the production of melanin and the substrates give the
color of skin, hair and eyes. Tyr is expressed specifically in melanocytes, the
pigment producing cells, and majority of melanoma cells.
Lineage tracing was performed using the Cre/loxp system with TYRCreERT2/ mT/mG mice. Briefly, in the TYR-CreERT2/ mT/mG mice, prior to Cre
recombination,

cell

membrane-localized

tdTomato

(mT)

fluorescence

is

expressed in every single cell. After tamoxifen/4HT induction, Tyr positive Cre
recombinase expressing cells (and future cell lineages derived from these cells)
show cell membrane-localized GFP (mG) fluorescence expression replacing the
red fluorescence (Figure 2.3A). In vivo lineage tracing of Tyr expressing cells in
the primary tumors can be performed on Dct-Grm1/ K5-Edn3/ TYR-CreERT2/
mT/mG mice by topical 4HT application using a small painting brush on the
primary tumor sites (Figure 2.3B).
The Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice obtained from the
mating of Dct-Grm1/ K5-Edn3 melanoma mice and TYR-CreRT2/ mT/mG mice
spontaneously develop primary and metastatic melanomas, and Cre inducible
Tyr positive cells that can be labeled with GFP making them distinguishable from
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the other red fluorescent labeled cells in the body. Because these mice were
obtained through breeding of several transgenic mice, the copy numbers of
transgenes essential for tumor development were dramatically diluted resulting in
a considerable delay in tumor appearance when compared to what was initially
reported in Chin, 2015 [38]. In Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice,
the first primary tumors appeared at an average of 7.5 month (n=25), which is 2.5
month longer than previously reported for the Dct-Grm1/ K5-Edn3 mice.
To validate the topical application methodology, dorsal skin of the TYRCreERT2/ mT/mG mice was topically painted and successful GFP labeling of
melanocytes in the hair follicles was observed, while other cells in the skin
retained the tdTomato red fluorescence color (Figure 2.3C). The same induction
method was applied to K5-Edn3/ TYR-CreERT2/ mT/mG mice, in which
accumulation of melanocytes outside the hair follicles at the dermal-epidermal
junction was expected [36]. Indeed, GFP+ green cells were found outside the
hair follicles (Figure 2.3D). To establish if the TYR promoter can also drive Tyr
expression in melanoma tumors in Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG
mice, topical painting of 4HT was performed on the tail tumors of Dct-Grm1/ K5Edn3/ TYR-CreERT2/ mT/mG mice. A mutually exclusive pattern of GFP and
tdTomato colors was found inside the tumors (Figure 2.3E).
2.2.3 Labeling of the Tyr Expressing Cells in the Primary Tumors
At an average of 7.5 month of age when the lesion first appeared as a
nevus (<1mm in height) on the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice,
I started 4HT topical administration. 4HT induction exclusively at an early stage
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was not sufficient to label the majority of Tyr expressing cells in the primary
tumors (Figure S1). To ensure the labeling of most Tyr expressing cells in the
primary tumors, 4HT topical administration was repeated for 3~4 weeks during
tumor growth until euthanasia. Numerous GFP+ cells were detected in
cryosections of primary tumors and lung metastases (Figure 2.4). To establish if
the GFP+ cells in the primary tumors expressed Tyr protein, cryosections of the
tumor were prepared soon after 4HT application and labeled with Tyr antibody.
GFP+ cells were found to be positive for Tyr immunoreactivity (data not shown).
2.2.4 Primary Tumor Derived Tyr Expressing Cells or Their Progeny Can
Reach the Lung and Seed Metastasis
The appearance of metastases in distant organs was established 2 weeks
to 7 months after the first 4HT painting of primary tumors. Micro-metastases,
characterized as clusters of less than 10 cells, were detected in 86% of lungs
examined (n=15). Each lung was sectioned and at least 20 cryosections per lung
were examined for the presence of primary tumor derived GFP+ cells. In 50% of
4HT painted Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice, GFP+ cells were
identified in various areas of the lung and other organs (Table S1). The number
of GFP+ cells found in the lung varied considerably, from 2 to 20 or more cells
per section. In most mice, the numbers were low, except for one mouse that
presented with pepper like micro-metastases and another one with macrometastases. No GFP+ cells were found in lungs of control mice (Dct-Grm1/ K5Edn3/ mT/mG) that had tumors painted with 4HT (n=10). Additionally, no GFP+
cells were detected in the lungs of mice that did not bear tumors (Dct-Grm1/ K5-
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Edn3/ TYR-CreERT2/ mT/mG) and had their dorsum painted with 4HT (n=3). The
location of the primary tumor affected the penetrance of GFP+ cells in the lung of
4HT painted Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice (Table S1). Only
one out of seven mice (1/7, 14%) that had only tail tumors painted, in contrast to
three out of four (3/4, 75%) mice that had only dorsal tumor painted, presented
with GFP+ cells in the lung. The only mouse with a dorsal tumor that did not have
GFP+ cells in the lung was painted only once at the nevus stage and no obvious
tumor growth was observed upon euthanasia.
The GFP+ cells were distributed into three categories depending on their
location in the lungs. The first category termed “inside the vessels” includes
intravascular solitary cells with an elongated and spindle shape found in close
association with the endothelial layer of the lung vasculature (Figure 2.5A). Cells
in this category were detected consistently, even on metastasis-free lungs,
providing support to the hematogenous dissemination of metastatic cells. The
second category termed “outside the vessels” consists of clusters of GFP+ cells
overlapping with the pigmented metastases (Figure 2.5B) with the possibility that
some may be still inside the alveolar capillaries. The rarest third category
consisted of solitary or tiny clusters (2~5) of cells outside the vasculature
displaying no pigmentation. Immunostaining showed that the GFP+ cell
populated metastatic lesions in the lung were positive for melanoma markers
TYR and TRP1 (Figure 2.5C, D), indicating the tumor initiating capacity of the
differentiated Tyr expressing cells or their progeny in the Dct-Grm1/ K5-Edn3/
TYR-CreERT2/ mT/mG mice. Of note, not all metastatic lesions in the lung
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contained GFP+ cells. This finding was not unexpected given that the efficiency
of the topical 4HT induction is not 100%, and that, primary tumor resident Tyr
negative cells might also metastasize.
2.2.5 Presence of Metastatic Cells inside the Lung Vasculature
Melanoma metastasis has been suggested as an inefficient process,
during which only a small number of cells can go through all the steps for a
clinically significant metastasis [39, 40]. It has been generally thought that most
metastatic cells are eliminated in the circulation [41]. In a small number of
animals (n=4) that were not subjected to cardiac PBS perfusion, lungs were snap
frozen immediately after euthanasia. In sections of these lungs, the blood vessels
were filled with blood but very few circulating GFP+ cells were found inside the
lumen of the vasculature (Figure S2E). Instead, we observed large numbers of
metastatic GFP+ cells associated with the pulmonary vascular endothelium or
invading the lung tissue. The number of GFP+ cells “inside the vessels” far
exceeded the micro- or macro-metastatic lesions “outside the vessels”. To find
out if GFP+ cells were proliferating, we performed Ki67 staining on the lung
sections where GFP+ cells were found. Double labeled GFP and Ki67 cells were
mostly confined to cell clusters “outside the vessels” (Figure 2.6E-H). In contrast,
the solitary GFP+ cells “inside the vessels” were mostly Ki67 negative, although
some Ki67+ cells were identified (Figure 2.6A-D). In the lungs of Dct-Grm1/ K5Edn3/ TYR-CreERT2/ mT/mG mice (n=3), the percentage of Ki67+ intravascular
GFP+ cells was less than 1% (Figure 2.7A). Disseminated cancer cells within the
circulation are exposed to the mechanical sheer stress, as well as immune
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surveillance, which may lead to rapid cell death [40, 42]. Most of the GFP+ cells
were found inside the vasculature including the big pulmonary arteries. To
determine if GFP+ cells had undergone apoptosis, we performed immunostaining
with an antibody against Cleaved Caspase 3. We were only able to detect a
small number of double labeled GFP + and Cleaved Caspase 3 + cells “inside
the vessels” (Figure S3). In the lungs of Dct-Grm1/ K5-Edn3/ TYR-CreERT2/
mT/mG mice (n=3), the percentage of Caspase 3+ intravascular GFP+ cells was
less than 3% (Figure 2.7B).
2.2.6 Presence of Perivascular Cellular Infiltrates in Metastatic Lungs
The detailed examination of lung cryosections of Dct-Grm1/ K5-Edn3/
TYR-CreERT2/ mT/mG mice where GFP+ cells were found, indicated the
presence of perivascular infiltrates in close proximity to the GFP+ cells. Notably,
the infiltrates were more obvious in lungs with micro-metastases (n=5) compared
with that with macro-metastases (n=2). Hematoxylin-eosin (H&E) staining
showed abnormal aggregates of cells surrounding the pulmonary vasculature,
among which brown pigmented macrophages were noticed (Figure 2.8A, B).
Small to no infiltrates were observed in GFP+ cell-free lungs. Fluorescence
immunostaining of the lung cryosections showed that the infiltrates were mostly
composed of CD45+ lymphocytes (Figure 2.8C), including CD3 positive T cells
(Figure 2.8D). Most cells within the infiltrates showed high levels of proliferation
as demonstrated by Ki67 immunoreactivity (Figure S4), suggesting the activation
of an immune response to the arrival of GFP+ metastatic cancer cells inside the
vasculature. These abnormal perivascular infiltrates found in lungs containing
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foreign GFP+ cells may add another explanation for the dormancy of
intravascular cancer cells.
2.2.7 GFP+

cells

Lose

Pigmentation

upon

Contact

with

Vascular

Endothelium
In order to detect any changes in the differentiation status of metastatic
cells, the pigmentation level of GFP+ cells was monitored as cells traveled from
the primary tumor to the lungs. At the primary tumor site, tissues deep
underneath the skin tumors containing blood vessels were collected and
sectioned. GFP+ cells were identified both inside and outside the vasculature
and interestingly, GFP+ cells inside the vasculature were not pigmented (Figure
2.9A, D, arrowhead) while GFP+ cells outside the vasculature were pigmented
(Figure 2.9A, D, arrow). This same dynamic pattern of pigmentation levels was
observed in the lung. Intravascular GFP+ cells in the lung vasculature were not
pigmented (Figure 2.9B, E, arrowhead), but resumed pigmentation production
while populating the lung metastases (Figure 2.9C, F, arrow).
2.2.8 Characterization

of

Metastatic

GFP+

Cells

Inside

Pulmonary

Vasculature
Given the loss of pigmentation by GFP+ cells as they entered the
vasculature, further characterization was necessary to establish their level of
differentiation. Immunostaining was performed on the lung cryosections with the
neural crest specific marker SOX10 (Figure 2.10A-D) and differentiated
melanocyte markers TYR and TRP1 (Figure 2. 10E-L). The GFP+ cells were
negative for all of them. The testing of other melanocytic lineage markers such as
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MITF and TRP2 also yielded negative results (data not shown). Based on the
stem cell model, it is possible that the differentiated Tyr expressing cells or their
progeny de-differentiated and transiently acquired stem cell properties. In
previous studies, P75 and Nestin were shown to selectively label melanoma
tumor initiating cells [13, 16, 17]. As such, we performed immunostaining with
P75 and Nestin on the lung cryosections where GFP+ cells were found, and the
results were also negative (Figure 2.10M-T). All fluorescence immunostaining
was done with a positive control to validate the indicated antibodies used, and
the staining results are representative of at least five mice.
2.2.9 Primary Tumor Derived Tyr Expressing Cells or Their Progeny Can
Reach other organs and Seed Metastasis
Regional lymph node metastasis is regarded as an indicator of metastasis
for many malignancies, including melanoma [43]. Although organ preferences of
melanoma metastasis are observed, they can spread widely in the body. Most
Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice with tumors showed enlarged
and hyperpigmented lymph nodes. Cervical lymph nodes were collected from
4HT painted mice and examined for GFP+ cells. Fifty eight percent (7/12) of the
mice with the presence of GFP+ cells in the lung also presented with GFP+ cells
in the lymph nodes (Table S1 and Figure 2.11). The enlarged lymph nodes of
Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice were rich with vessels
(blood/lymphatic). The staining pattern of TYR in lymph nodes occupied by GFP+
cells was different from that in the lung. The GFP+ cells in lymph nodes were
more heterogeneous, both TYR+ (Figure 2.11, arrowhead) and TYR- (Figure
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2.11, arrow) GFP+ cells were found. Additionally, TYR+ cells that were not GFP+
were also observed (Figure 2.11, star) indicating either the insufficiency of 4HT
topical induction or the presence of non-Tyr expressing cell subpopulations.
The most common sites of visceral metastases in the Dct-Grm1/ K5-Edn3/
TYR-CreERT2/ mT/mG mice were lungs, with only one mouse (1/15) showing
evident kidney and spleen metastases. The GFP+ cells were found inside the
metastatic foci of the kidney and spleen (Figure S2F-I), further demonstrating the
tumor initiating potential of the primary tumor derived Tyr expressing cells or their
progeny.
The Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice spontaneously
develop multiple melanocytic tumors on the skin, all of which were presumed as
primary tumors. However, it is plausible that cells from the first dorsal/tail tumor
spread and seeded the secondary dorsal/tail tumor at different sites of the
dorsum/tail. In three Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice, the dorsal
tumors and only one tail tumor were subjected to topical 4HT painting. One tumor
per mouse that appeared later and was not painted was checked for the
presence of GFP+ cells. Interestingly, non-painted tumors from the three mice
were mainly constituted by GFP+ cells (Figure S5). To exclude the inappropriate
spread of 4HT from grooming behavior, the non-painted tumors examined were
chosen as far as possible from the painted ones, for example, a non-painted tail
tumor proximal to the body vs. a painted tail tumor distal to the body; a nonpainted dorsal tumor on top of right hind leg vs. a painted dorsal tumor on left
flank. Although we could not establish whether the tumorigenic GFP+ cells giving
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rise to the non-painted tumor were dorsal tumor-derived or tail tumor-derived, the
result presented here further proved the tumor initiating capacity of Tyr
expressing melanoma cells or their progeny.
2.2.10 Metastatic

Melanoma

Cells

Disseminate

Early

during

Melanomagenesis
Late recurrence is fatal and has been shown clinically in melanoma
patients who have gone through primary tumor resection at early diagnosis.
Although greater than 85% cutaneous melanoma patients can be cured after the
removal of the primary tumors, a small number of patients may show recurrence
as late as 15-20 years [44]. This not only indicates the existence of metastasis
dormancy but also suggests that metastatic melanoma cells may disseminate
into the circulation system much earlier than previously expected. To test this, we
grouped the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice into three stages,
before nevus stage (n=3, no noticeable nevus or tumor was observed), nevus
stage (n=3, <1mm in height) and tumor stage (n=3). We painted 4HT on the
nevus or tumor as described previously. For the before nevus stage group,
painting of 4HT was performed 3-4cm from the end of the tail. The tails with the
painted area were collected and sections containing blood vessels were
analyzed for the presence of GFP+ cells. The GFP+ cells were found inside the
tail vasculature at all three stages (Figure 2.12). The results indicate that
tumorigenic cells acquire and maintain the ability to enter the circulation at all
times during the process of tumorigenesis, even prior to the formation of a
sizable tumor.
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2.3 Discussion
Melanoma, the deadliest type of skin cancer, still imposes a great
challenge for therapy because of its highly aggressive nature to metastasize to
distant organs. As an important step of preclinical research, some melanoma
murine models have been developed, including xenograft, syngeneic, and
genetically engineered models, to help understand the mechanisms of melanoma
progression or develop promising therapies to melanoma patients. It is generally
believed that genetically engineered models are better options compared with
xenograft or syngeneic models in regard to anticancer drug assessment [45].
Among the genetically engineered melanoma mouse models that have been
developed, some require extra carcinogens to induce melanoma, such as UV
exposure, which adds to the cost and labor-intensive interbreeding of multiple
mouse strains. More important, few of the genetically engineered melanoma
mouse models were reported to develop visceral metastases, which limits the
study of melanoma metastasis. Of the several melanoma mouse models that
show distant metastasis, some of them already employed Cre/loxp to induce
tumors, preventing us from using the Cre/loxp system for lineage tracing [46, 47].
The Dct-Grm1/ K5-Edn3 mice, to our knowledge, is the first spontaneous
melanoma metastasis mouse model that is free of oncogenes and dependent
exclusively on the presence of signaling pathways. The tumor metastasis
process of these mice closely resembles that in human melanoma patients given
the variability in time to tumor and appearance of metastasis. Although the DctGrm1/ K5-Edn3 mice provide us with an optimum system for lineage tracing of
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metastatic cells within an unperturbed tumor environment, the number of
samples that can be obtained within a reasonable amount of time is limited. In
the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice where lung metastases are
identified, the terminal fate of those labeled cells in the secondary organ can be
determined and perhaps more interesting, the dynamic changes in genotype and
phenotype during the metastatic process can also be investigated.
To spatially restrict Cre induction within the primary tumors, we topically
applied

4HT

on

the

tumors

instead

of

systemic

administration.

4-

hydroxytamoxifen topical application has been successfully used in other studies
for site specific Cre induction [48-50]. The fact that GFP+ cells were absent in
some lungs with pigmented metastases attests to the spatial restriction of Cre
induction, given that all melanocytic lesions should be labeled with GFP if
systemic administration of 4HT through blood happened. In addition, the absence
of GFP+ cells in some pigmented lesions, but not others, in the same lung further
excluded the possibility of 4HT systemic administration. In other words, GFP+
cells found in the lung can only be derived from the dorsal/tail tumor that were
4HT painted. Although labeling of Tyr expressing cells may not be 100% efficient,
this should not constitute a problem for this study considering the abundance of
differentiated cells in the melanoma lesions. It is important to bear in mind that
cancer is complex and dynamic. As tumors grow, they may recruit more
melanocytes located in the dermal-epidermal junction, and it is also possible that
stroma cells transdifferentiate into Tyr expressing melanocytes as it was shown
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that a combination of three factors, MITF, SOX10 and PAX3, were sufficient to
convert mouse and human fibroblasts to functional melanocytes in vitro [51].
The heterogeneity of tumors including melanoma has been recognized for
decades pointing to the varied tumor initiating capacities of cell subpopulations
within the solid tumors [52]. While some studies have confirmed that cells that
express melanoma stem cell markers have tumor initiating capacity, they have
mostly focused on primary tumor formation not metastasis. The robustness of the
stem cell markers used in these studies is also controversial based on the use of
xenotransplantion assays [13-17]. Here, using Cre/loxp system, we genetically
labeled Tyr expressing cells within the primary tumors in the Dct-Grm1/ K5-Edn3/
TYR-CreERT2/ mT/mG mice and tracked the fate of the labeled cells by lineage
tracing. We demonstrated that the more differentiated Tyr expressing cells can
also be the progenitors of tumor initiating cells and seed distant metastases in
various organs successfully in mice. However, what we have shown does not
refute entirely the stem cell scenario in that gene expression profiles are dynamic,
and it is possible that GFP+ cells de-differentiated to a more stem cell-like state
after the labeling. This is also supported by the fact that GFP+ cells lost their
pigmentation, as well as melanocytic lineage markers while in contact with the
vascular endothelium, but, regained those features after seeding metastases.
The fact that tumor cells are plastic increases the complexity of the
melanomagenesis process, suggesting that the tumor initiating potential of
melanoma cells may be underestimated and the spatial and timing elements
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should be considered when a melanoma stem cell marker is defined or
characterized.
Metastasis disease is the primary cause of death in cancer patients.
Although prolonged survival occurs as a result of the development of newr
therapies and better understanding of the metastatic mechanism, the early
diagnosis of cancer metastases has always been a challenge. In general, human
tumor metastasis consists of a series of biological processes including:
metastatic cells leave the primary tumor, invade into surrounding tissues and
enter the blood or lymphatic vessels, travel through the circulatory system, arrest
at the distant organs and finally seed successful metastases [53, 54]. Most
studies on melanoma metastasis were either focused on the first stage (primary
tumors) or the last stage (metastatic tumors). Gene microarray data from
different stages of melanoma progression were analyzed and shed light on the
mechanism of metastasis [55-58]. Metastatic tumor cells in circulation have been
long recognized, and CTCs in the blood stream have been successfully isolated
from human blood [59-61]. An FDA approved detection system, Cellsearch, is
available for the isolation of CTCs and has been successfully used for monitoring
patients with metastatic breast, prostate and colon cancers [62]. Nonetheless, no
consensus has been reached regarding melanoma CTCs because of sample
scarcity, cohort heterogeneity, and the application of Cellsearch on melanoma
patients seems not sensitive enough and needs further investigations [63]. The
development of real-time imaging techniques, such as non-invasive methods or
intravital microscopy, make it possible to study the dynamic process of cancer
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metastasis [64-66], including melanoma [67, 68]. However, real time imaging
cannot investigate the genetic diversity of the metastatic tumor cells, and most in
vivo real time imaging has been based on cell injection, xenograft or syngeneic
transplantations,

bypassing

the

complexity

of

endogenous

tumor-host

interactions. In our study the use of a spontaneous melanoma mouse model
depending on GRM1 and Edn3 signaling pathways allowed us to characterize
the dynamic gene expression profiles of metastatic cells in relationship to their
spatial distribution during the journey from primary tumor sites to secondary
organs and represents a tremendous advantage in understanding mechanisms
associated with melanoma metastasis.
It is noteworthy that the better studied CTCs are not necessarily the
contributors of metastases or recurrence, instead, disseminating cells that
survive after infiltrating distant organs, may be more dangerous since they can
be dormant anywhere as invisible, undetectable solitary or cluster of cells.
Studies about metastatic dormancy on a variety of cancers have been increasing
[62, 64, 69], but little attention has been paid to metastatic dormancy of
melanoma. During the discussion between members of the Melanoma Research
Foundation (MRF) Scientific Advisory Council and Breakthrough Consortium in
2015, Merlino et al. highlighted melanoma dormancy as one of the four thematic
areas and raised the issue that study of melanoma dormancy lagged significantly
behind that of breast and prostate cancers and research about this area was
required [70].
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Although it has been proposed that metastatic dormancy of melanoma can
be established directly at the target organ [70], in vivo evidence is missing. The
best studied location of metastatic dormancy in cancers is the bone marrow [7173], as has been shown in the only melanoma dormancy study with the Ret
transgenic mouse model [74]. The data presented in this study suggested that
the vascular endothelium in the target organ can act as a potential reservoir for
metastatic melanoma cell dormancy. We found that the primary tumor derived
metastatic melanoma cells associated with the pulmonary vascular endothelium
did not proliferate or undergo apoptosis, recapitulating the state of metastatic
dormancy. As a consequence of the limitation of our model, identification of the
fate of each individual cell is impossible, as such, we cannot conclude that the
dormant melanoma cells inside the pulmonary vasculature are the ones that exit
and seed the overt metastases after reactivation. The CTCs may also be
possible contributors [75].
Late recurrence of melanoma has been reported, and the recurrence site
is commonly the lungs [76]. If the presence of putative dormant metastatic cells
in the vasculature of the lung also occurs in human patients, stopping therapies
in patients who are thought to be disease free may have dire consequences. The
mechanism used by disseminated tumor cells to survive in immunocompetent
individuals for an extended period of time is one of the biggest conundrums in
tumor immunology. A possible explanation is what has been called tumor
immunoediting: genetically and epigenetically unstable tumor cells can adapt to
immune attack by either down regulating tumor associated antigens or shutting
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down death signaling pathways [77]. The loss of the melanocytic/melanoma
markers by the GFP+ cells may represent this concept of immunoediting.
Although viable, the outgrowth of the dormant tumor cells is restrained by the
adaptive immunity. Koebel et al. called this process “equilibrium” and they
provided evidence that tumor cells in equilibrium were highly immunogenic
whereas the outgrowing tumor cells were not [78]. This is in line with the results
obtained with the Ret transgenic mouse model where it was shown that bone
marrow melanoma-specific memory T Cells were detectable and functionally
active in tumor free mice [74] and that CD8+ T cells could delay the visceral
metastases in the mice [79, 80]. Stronger evidence of the tumor-immune
“equilibrium” can be obtained from clinical reports of donor derived melanoma
through transplantation surgeries [81-84]. In our study, the fact that lymphocytes
in the perivascular infiltrates were found in the lungs where dormant melanoma
cells were identified but not obvious in lungs with full-blown metastases can be
explained by the immune equilibrium. Yet, further investigation is needed to
elucidate the mechanisms underlying the interplay between immune cells and
dormant metastatic cells.
Early dissemination of abnormal cells has been detected in murine models
of various cancers [85-89]. Numerous cases of patients with metastatic
melanoma free of detectable primary tumors have been reported clinically [90-95].
The presence of GFP+ cells inside the vasculature at all stages during the
process of tumorigenesis, even prior to the formation of a sizable tumor indicated
the early dissemination of melanocytes. Although there is a high chance that
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these intravascular GFP+ cells disseminating early into tail vasculature are just
dormant and not fully malignant, this still constitutes strong evidence that
prospective metastatic melanoma cells may enter the circulation system before
the formation of primary tumors. The study showing untransformed mouse
mammary cells in the circulation could acquire malignant growth upon oncogene
activation

further

argued

the

possibility

that

untransformed

cells

that

disseminated early could account for the later metastases [87].
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A

Figure 2.1 Heterogeneity of melanomas from different transgenic mice.
A and B, HGF/SF mouse; C and D, Dct-Grm1/K5-Edn3 mouse; E and F, DctGrm1/K5-Edn3/Dct-Ednrb mouse. A, C and E indicate Nestin and TRP1
immunostaining of paraffin-sections. B, D and F indicate Nestin and P75
immunostaining of paraffin-sections. Note the distinct cell subpopulations in the
same solid tumor.
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Figure 2.2 Mouse model of melanoma metastasis.
Dct-Grm1/ K5-Edn3 mice spontaneously develop melanocytic lesions on the ear,
tail and dorsal skin (A) and metastases in the lung (B). The pigmented lesion in
the lung is positive for melanoma marker TRP1 (C is the bright field of D).
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Figure 2.3 Mouse model of melanoma metastasis.
Diagram shows how Cre/loxp system was used with mT/mG loxp reporter mice
and TYR promoter/enhancer controlled Cre expression in TYR-CreERT2 mice (A).
An in vivo lineage tracing system can be established on the progeny mice
carrying all the transgenes from TYR-CreERT2/mT/mG and Dct-Grm1/ K5-Edn3
mating. Instead of systemic administration, 4HT was topically applied to the
primary tumor sites to exclusively label Tyr expressing cells inside the tumor, not
the other sites. Lineage tracing of the GFP+ cells during melanoma metastasis is
achievable (B). 4HT topical application was validated on both TYR-CreERT2/
mT/mG mice, where melanocytes are located inside hair follicles (C, arrow), and
K5-Edn3/ TYR-CreERT2/ mT/mG mice, where melanocytes outside the hair
follicles are also expected due to the abundant Edn 3 in the environment (D,
arrow). This methodology was also valid in the melanoma mouse model DctGrm1/ K5-Edn3/ TYR-CreERT2/ mT/mG. 4HT painted tail tumor cryosections
were directly visualized under fluorescent microscope. Numerous green cells
were found inside the tumor, consistent with the abundance of Tyr expressing
differentiated cells in melanoma (E). Green, GFP+ melanocytes; Red, tdTomato,
expressed in all non-recombined cells; Blue, nuclei counterstained with DAPI.
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Figure 2.4 Labeling of the Tyr expressing cells in the primary tumors.
4HT was topically painted on the dorsal (A) or tail tumors of Dct-Grm1/ K5-Edn3/
TYR-CreERT2/ mT/mG mice, lung metastases with pigmentation were found after
the mice were euthanized(C). Cryosections of the dorsal tumor were directly
visualized under the fluorescence microscope and numerous GFP+ cells were
found (B).

68

Figure 2.5 Lineage tracing of tumorigenic cells to the lung.
GFP+ cells were found in the lung, most of which were located at the inner wall
of vasculature as single cells with an elongated, spindle shape (A), clusters of
green cells were mainly seen in the lung metastatic foci (B, insert: bright field of
the boxed area, showing green cells overlapped with pigment). GFP+ cell
populated metastases in the lung were TYR and TRP1 positive showing the
successful seeding of melanoma metastases (C, D).
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Figure 2.6 Primary tumor derived GFP+ cells proliferated in the lung.
Top panel (A-D) showed one GFP+ cell located at the inner layer of the lung blood vessel (the green cell was
located at the longitudinal section part of the vasculature) was positive for Ki67. Lower panel (E-H) showed one
GFP cell inside the pigmented micro-metastasis expressed Ki67. Red, Ki67; green, GFP from the Cre induction or
anti-GFP antibody used to amplify the signal for immunostaining; blue, DAPI.
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Figure 2.7 Numbers of Ki67 or Caspase3 staining of intravascular GFP+ cells in
the lung.
Less than 1% Ki67+ and less than 3% Caspase3+ intravascular GFP+ cells were
identified in the lung of Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice.
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Figure 2.8 The presence of GFP+ cells in the lung was associated with
perivascular infiltrates.
Hematoxylin-eosin (H&E) staining (A, B) of lung cryosections from Dct-Grm1/ K5Edn3/ TYR-CreERT2/ mT/mG mice, of which primary tumor derived GFP+ cells
were found. Perivascular cellular infiltrates were shown in the lung. B, a higher
magnification of the cellular infiltrates, brown pigmented macrophages were seen
inside the infiltrates. Immunostaining with indicated markers showed the
perivascular infiltrates were mostly CD45 (lymphocyte common antigen) positive
(C), and some were T cell marker CD3 positive (D). Note, one GFP+ cell was
shown inside the vessels in C and D.
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Figure 2.9 Pigmentation level of GFP+ cells during metastasis.
GFP+ cells lost pigmentation while they were inside the vasculature at the tail
tumor site (A, D, arrowhead) and in the lung (B, E, arrowhead), but produced
pigmentation when they were outside the vessels (A, D, arrow) or within the
metastatic foci (C, F, arrows). D-F are bright fields of A-C, respectively.
Cryosections were counterstained with DAPI.
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Figure 2.10 Immunostaining of GFP+ cells in the lung vasculature of Dct-Grm1/
K5-Edn3/Tyr-CreERT2/mT/mG mice.
GFP+ cells in contact with lung vasculature (A, E, I, M, Q) did not express Sox10,
TYR, TRP1 (B, F, J), P75, Nestin (N, R). Staining was performed on cryosections
with appropriate positive controls to validate the indicated antibodies.
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Figure 2.11 Characterization of GFP+ cells in lymph nodes.
TYR staining was done on the lymph node cryosections where GFP+ cells were found. Some GFP+ cells inside the
lymph nodes expressed TYR (arrowhead), while some did not (arrow). A-D, a lower magnification; E-H, a higher
magnification showed GFP+ cells inside the vasculature. Some TYR positive cells are not GFP+ (star).
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Figure 2.12 Timing of metastatic GFP+ cell dissemination.
4HT was painted on nevus or tumor or normal skin of the tail. Cryosections of the tail with the painted area were
immunostained with CD31 to localize blood vessels underneath the tail skin. GFP+ cells were found inside the tail
vasculature at all three stages. GFP, green; CD31, red; DAPI, blue. Only the vasculature underneath the painted
area is shown, not the actual nevus/tumor/skin.
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CHAPTER
3.

PHENOTYPIC PLASTICITY OF METASTATIC MELANOMA
CELLS
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3.1 Introduction
The vasculature plays an essential role in cancer progression. Most
studies that have implicated the vasculature as a key factor in tumorigenesis
have focused on the process of angiogenesis [1]. However, there is some
evidence that angiogenesis may not be required for metastasis and other
mechanisms such as vessel co-option have been suggested as an alternative [2].
In vessel co-option, tumor cells hijack and migrate along preexisting vessels of
the host organs. Vessel co-option has been observed in human primary tumors
and metastases and is most frequently described in highly vascularized tissues
such as brain, lung, and liver [2]. Vessel co-option was detected in melanoma,
and proposed to be the process employed by tumors to continue growing after
antiangiogenic therapies [3, 4].
Another alternative pattern of tumorigenic functional microcirculation that
has received special attention is VM where tumor cells acquire the capacity to
form

endothelial-like

vessels

recapitulating

embryonic

vasculogenesis.

Vasculogenic mimicry is a striking example of tumor plasticity where tumor cells
can transdifferentiate into an endothelial-like phenotype and express vascular
related molecules. Numerous VM studies in distinct cancers have been published
since the first introduction of this concept in 1999 [5, 6]. Vasculogenic mimicry
was first described in the context of human melanoma cells [6] and originally
defined as the ability of aggressive melanoma cells to form CD31 negative but
Periodic acid schiff positive vascular-like networks. Periodic acid schiff stains
basement membranes including laminin, collage and glycogen and CD31 is an
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endothelial cell specific marker. Later, the same group provided the first direct
evidence that another endothelial-associated molecule, vascular endothelial
(VE)-cadherin, was exclusively expressed by highly aggressive melanoma cells
and dispensable for VM [7]. Signaling pathways underlying VM with a focus on
VE-cadherin expression were recently reviewed [8]. Although absence of CD31
is a characteristic of VM in melanoma, CD31 expression was reported in VM
capable cell lines from ovarian cancer [9], prostatic cancer [10] and breast cancer
[11]. Distinct contributions of VE-cadherin and CD31 in vessel formation [12] and
embryonic origins of the tumor cell types may provide some clues to the selective
expression of these two genes, but further investigations are needed to elucidate
their specific roles in VM [13].
Tumor cells in various cancers, including melanoma, that are capable of
VM share the “stemness” feature [14-19]. Gene-expression profiling of more than
45 human cutaneous and uveal melanoma-cell lines showed that, compared with
the poorly aggressive melanoma cells, highly aggressive melanoma cells downregulated melanoma-specific markers including MITF, TYR, TRP1 and
upregulated angiogenesis and vasculogenesis genes such as VE-cadherin,
erythropoietin-producing hepatocellular carcinoma-A2 (EPHA2), and laminin 5
γ2-chain (LAMC2) [13]. The interplay between tumor cells acquiring endotheliallike and stem cell-like features may be what allows VM to participate in tumor
metastasis or recurrence. The functional significance of VM is not well
understood, but it may be involved in facilitating tumor perfusion and
dissemination.

Vasculogenic

mimicry
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is

positively

related

with

tumor

aggressiveness and an overall shorter survival time [20-22]. Vascular
endothelial-cadherin positive melanoma cells co-expressing the stem cell marker
CD133 engaged in VM creating a perivascular niche essential for primary tumor
growth in mouse xenografts [19]. Another study by Wagenblast et al., linked VM
in primary tumors with distant metastases in a breast cancer tumor mouse model.
They provided evidence that Serpine2 and Slpi not only played essential roles for
VM, but, as anticoagulants, also promoted metastatic cell intravasation and
ultimate metastases by maintaining perfusion of the tumor cell-lined networks at
the vascular/extravascular interface [23].
Another special pattern of vasculature in tumors is mosaic vessels, where
vessels contain both authentic endothelial cells and tumor cells. Mosaic vessels
in tumors were first observed in colon carcinoma, featured by discontinuous
endothelial marker CD31 expression in tumors [24]. Mosaic vessels in
hepatocellular carcinoma were also reported [25]. One of the proposed potential
mechanisms of mosaic vessel formation [26] lies in the plasticity of highly
malignant tumor cells, suggesting tumor cells can mimic the endothelial cells thus
displace endothelial cells of the vessel lining. Whereas mosaic vessel features
the endothelial-like behavior of cancer cells, those cancer cells being part of the
vasculature do not express the typical endothelial cell marker CD31.
Vessel co-option differs from VM and mosaic vessels in that it is a nonangiogenesis mechanism. Tumorigenic cells take advantage of the preexisting
vasculature for tumor growth or migration. While vessel co-option has not been
associated to the process of angiogenesis, VM and mosaic vessels have been
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studied within its context. All studies about VM and mosaic vessels were carried
out to demonstrate their relevance for primary tumor outgrowth and no
correlation to the metastatic process has been established. Although some
authors have hypothesized a functional role for VM and vessel co-option in
facilitating tumor cell dissemination, no direct evidence is available. In the
present study, I show a novel tumor-vasculature pattern observed in a
spontaneous melanoma mouse model. In the new pattern, melanoma metastatic
cells transdifferentiate into endothelial cells, hijack the existing vasculature at the
metastatic sites and assemble an intravascular niche. I propose that in this niche
metastatic cells are allowed to survive as dormant cells and re-acquire metastatic
properties for latent spread.
3.2 Results
3.2.1 Vascular Endothelium Associated GFP+ Cells Express Endothelial
Cell Markers
In the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice, most metastatic
GFP+ cells in the lung were located inside the pulmonary vasculature. To
establish the exact intravascular location of GFP+ cells in the lung, we labeled
the lung cryosections where GFP+ cells were found with an antibody against
CD31 to identify the vascular endothelial cells. To our surprise, the average of
intravascular GFP+ cells was CD31 staining was also observed in approximately
70% of the GFP+ cells associated with the vascular endothelium (Figure 3.1, top
panel), including solitary GFP+ cells in alveolar capillaries (Figure S6). To further
confirm the acquisition of an endothelial phenotype by the GFP+ cells, we used
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another endothelial cell marker, VE-cadherin, a similar percentage of
intravascular GFP+ cells also labeled with VE-cadherin demonstrating their
endothelial nature (Figure3.1, bottom panel).
Since CD31 and VE-cadherin are expressed in the membrane at the cellcell junction it is plausible that the staining detected was in fact associated with
the vascular endothelial cells surrounding the GFP+ cells. In order to fully
establish which cell type was immunolabeled with the antibodies against CD31
and VE-cadherin, small segments (2-3mm length) of pulmonary artery,
pulmonary vein and aorta were obtained from 4HT painted mice and visualized
directly by confocal microscopy. Since all cells in Dct-Grm1/ K5-Edn3/ TYRCreERT2/ mT/mG mouse express tdTomato red fluorescence protein except
GFP+ Tyr expressing cells or their progeny, whole mount visualization of the
vessels allowed us to detect the presence of GFP+ cells directly. As shown in
Figure 3.2, primary tumor derived GFP+ cells were found in all three vessels. Of
note, GFP+ cells were always located in association with or within the vascular
endothelial layer, not the outer smooth muscle layer. The GFP+ cells embedded
into the endothelium resembled the vascular endothelial cells morphologically. It
is noteworthy that GFP+ cells changed their morphology according to the
vascular endothelium where they were found (Figure 3.2, i.e., vein associated
GFP+ cells showed a different shape compared with the artery associated ones),
further indicating the plasticity of tumor cells. Whole mount staining of CD31 and
VE-cadherin was carried out on the vessels and 3D reconstruction showed
results consistent with the ones obtained from the lung cryosections. The GFP+
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cells associated with the vasculature were clearly positive for CD31 and VEcadherin (Figure 3.3).
3.2.2 Expression Pattern of Endothelial Cell Markers by GFP+ Cells is
Dynamic
The

phenotypic

plasticity of

GFP+

cells

was

demonstrated

by

characterizing the expression of endothelial cell markers during tumor
progression. In the primary tumors, GFP+ cells did not present detectable CD31
expression (Figure 3.4A). In contrast, the majority of primary tumor resident
GFP+ cells were VE-cadherin positive (Figure 3.4D), a feature of VM. In the lung
vasculature, GFP+ cells associated with the vascular endothelium expressed
both CD31 (Figure 3.4B) and VE-cadherin (Figure 3.4E). GFP+ cells populating
the lung metastases lost the expression of both endothelial cell markers (Figure
3.4C, F). The fact that GFP+ cells lost CD31 expression when they seeded the
metastases was expected given that they originally did not express it in the
primary tumor. It was surprising that they lost VE-cadherin expression as well, in
that they were VE-cadherin positive at the beginning of the metastatic journey.
As for what occurred in blood vessels, GFP+ cells also showed endothelial
cell mimicry in lymphatic vessels. In the lymph nodes of Dct-Grm1/ K5-Edn3/
TYR-CreERT2/ mT/mG mice, GFP+ cells were found associated with the
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) positive lymphatic
vessel cells. LYVE-1 is strongly expressed by endothelial cells of normal
lymphatic vessels but not blood vessels [27]. 90% of the intravascular (LYVE-1+
cell-lined vessels) GFP+ cells were also LYVE-1 positive (Figure 3.5A). GFP+
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cells that were associated to the lymph node blood vessels (LYVE1-/CD31+)
expressed CD31 (Figure 3.5B) consistent with the results obtained from lung
blood vessels. Although LYVE-1 can be used as a lymphatic vessel marker to
discriminate lymphatic vessels from blood vessels in most tissues, it has been
demonstrated to label various blood vessels in the mouse lung [28-30]. Indeed,
we performed double immunostaining of CD31 and LYVE-1 on lung cryosections
and found them to overlap considerably. In contrast, LYVE-1 only labeled the
lymphatic vessels in lymph nodes though weak CD31 staining on some lymphatic
vessels was also observed (data not shown). We found LYVE-1+/CD31+
intravascular GFP+ cells in the lung, but we cannot confirm the type of vessels
they were associated with. However, GFP+ cells within the metastatic foci in the
lung did not express LYVE-1 (Figure 3.5C).
3.2.3 EndMT as a Potential Mechanism Underlying Dormant Tumor Cell
Awakening
Since the intravascular GFP+ cells in the metastatic sites acquired an
endothelial cell phenotype, we wanted to find out if they could undergo EndMT as
a way to regain the capacity to establish successful metastases. Endothelialmesenchymal transition has been proposed as an important mechanism that
underpins the role played by tumor-derived endothelial cells in tumor progression
[31]. The hallmarks of EndMT are the acquisition of the mesenchymal markers
VIMENTIN and -smooth muscle actin (-SMA). We performed VIMENTIN and
-SMA immunostaining on lung cryosections where GFP+ cells were found.
VIMENTIN positive intravascular GFP+ cells were found in various areas of the
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lung (Figure 3.6, arrowhead), but heterogeneity existed even between cells in
close proximity (Figure 3.6, arrow). -SMA+ GFP+ cells were also identified in
the lung. Interestingly, some CD31+/-SMA+ GFP+ cells were found inside
alveolar capillaries (Figure 3.7, arrowhead), indicating an intermediate state of
EndMT. Figure 3.8 shows the heterogeneity and plasticity of a small cluster of
GFP+ cells located in an alveolar capillary with both CD31-/-SMA+ (Figure 3.8,
arrow) and CD31+/-SMA+ (Figure 3.8, arrowhead) GFP+ cells. It is noteworthy
that -SMA+ GFP+ cells were only found in smaller vessels (arterioles,
capillaries). In contrast, GFP+ cells associated with larger vessels (pulmonary
arteries) were always -SMA negative, and found wrapped around the -SMA+
smooth muscle cells and vascular endothelial cells (Figure 3.9)
3.2.4 Plasticity and Heterogeneity of Metastatic GFP+ Cells
The phenotypic change of GFP+ cells as they progressed from the
primary tumor to the site of metastasis may require an initial process of dedifferentiation so they can acquire a novel fate. To evaluate if the intravascular
GFP+ cells may also have gone through a stem-cell phenotype, immunostaining
with the stem cell markers SOX2 and OCT4 was performed on lung cryosections
of Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice. SOX2 and OCT4 positive
metastatic melanoma cells were identified, but as for all the other markers tested,
the staining pattern was quite heterogeneous (Figure 3.10).
Connexin43 (Cx43) was shown to be involved in tumor/vascular
endothelial cell communication in highly metastatic melanoma cells [32] and
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breast cancer cells [33]. Stoletov et al. showed that metastatic melanoma and
breast cancer cells used Cx43 to initiate brain metastatic lesion formation in
association with the vasculature [34]. Similarly to what they found, we detected a
small population of GFP+ metastatic melanoma cells associated with the
vascular endothelium that were Cx43 positive (Figure 3.10).
The heterogeneity and plasticity of primary tumor derived GFP+ cells were
also observed in other metastatic organs. Immunostaining of VE-cadherin was
performed on spleen and kidney cryosections from the Dct-Grm1/ K5-Edn3/
TYR-CreERT2/ mT/mG mouse where visible metastases were found. It is
intriguing that no detectable or weak signal of VE-cadherin immunoreactivity was
found on GFP+ cells scattered in the spleen and kidney, whereas GFP+ cells
within the metastatic foci in the spleen were positive for VE-cadherin (Figure
3.11A). S100 is used clinically for melanoma diagnosis, and we performed S100
immunostaining on the lymph node cryosections where GFP+ cells were found.
S100 was highly expressed in the metastatic lymph node but intravascular and
circulating GFP+ cells did not show S100 expression (Figure 3.11B).
3.3 Discussion
In our study, we found that primary tumor derived Tyr expressing cells or
their progeny mimicked endothelial cells when in contact with blood or lymphatic
vascular endothelium during metastasis but lost the endothelial phenotype in the
lung metastatic foci. The strong association between vascular endothelial cells
and GFP+ tumor cells observed in the spontaneous mouse melanoma model
Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG is reminiscent of VM and mosaic
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vessels. However, it is obviously distinct from these two mechanisms in that 1)
the association was observed in metastatic sites not primary tumors, 2) GFP+
cell associated with original vasculature of the circulatory system, not newly
formed vessels, 3) the metastatic GFP+ melanoma cells associated with the
vascular endothelium were CD31 positive. Despite of these distinctions, similarity
is evident because all these previously described mechanisms underlie the
phenotypic plasticity of cancer cells by mimicking vascular endothelial cell
properties. The possibility that metastatic GFP+ cells associated with the
vasculature may achieve long-term survival because of the easy access to
oxygen and nutrients also mirrors another tumor-vasculature pattern, vessel cooption. But then again, the intravascular location of the GFP+ cells is different
from that where tumor derived cells are found in vessel co-option.
A recent review by Sun et al. suggested that a connection exists between
VM and epithelial-to-endothelial transition (EET). They identified hypoxia, high
interstitial fluid pressure and ECM remodeling as the likely factors that promote
EET [35]. On the basis of the data provided in this study, we propose a
melanoma (which is better characterized as a mesenchymal cell)-to-endothelial
transition or transdifferentiation. This is not the first time that such a transition is
suggested in the context of cancer.

Tumor-derived endothelial cells were

recognized decades ago in human B-cell lymphoma and human neuroblastoma
when tumor specific chromosomal alterations were identified in tumor endothelial
cells through fluorescence in situ hybridization [36, 37]. Notwithstanding, the
transdifferentiation of tumorigenic cells into endothelial cells was only recently
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characterized in glioblastoma (GBM) using in vitro and in vivo evidence. In vitro,
human glioma stem progenitor cells transdifferentiated into endothelial cells and
formed tubular-like structures when cultured in endothelial differentiation medium.
The expression of the endothelial markers CD31, CD34 and Von Willebrand
factor (vWF) in glioma cells was induced by hypoxia or oxygen–glucose
deprivation [38]. The in vivo evidence showing that GBM tumor cells
transdifferentiated into CD31+ endothelial cells was first demonstrated through
xenotransplantation. The authors found a GBM stem cell CD133+ subpopulation
that had the capacity to differentiate along both tumor and endothelial cell
lineages, and implicated VEGF and Notch pathways as important in this process
[39]. These observations were corroborated by another group, who detected that
a variable number (range 20–90%) of endothelial cells in human glioblastoma
carried the same genomic alteration as tumor cells [40]. Glioblastoma cell to
endothelial transdifferentiation was also reported in a syngeneic C6 glioma rat
model [41] and xenotransplantation assay by Shaifer’s group [42]. Stronger
evidence emerged from a study on a novel GBM mouse model using Cre/loxpcontrolled lentiviral vectors for tumor formation [43]. Tumor cells were labeled
with GFP when lentiviral induced tumor formation happened and, notably, GFP+
tumor cells that associated with the vasculature expressed vWF, CD31, CD34
and CD144. Further in vitro differentiation experiments revealed that hypoxia and
independence of VEGF underlie the mechanism responsible for the cancer cell
into endothelial cell transdifferentiation [44]. The latter was also shown by Seno’s
group using miPS-LLCcm cells (a representative mouse induced pluripotent stem
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cells, miPS, converted with culture medium from Lewis lung carcinoma cells)
both in vitro [45-47] and in vivo [18].
But why do tumor cells masquerade as endothelial cells? We showed in
Chapter 2 that intravascular GFP+ cells in the lung of Dct-Grm1/ K5-Edn3/ TYRCreERT2/ mT/mG mice lost melanocytic lineage markers and recapitulated the
state of dormancy. If the transdifferentiation of melanoma cells into endothelial
cells is the next step in the process, then endothelial cell mimicry may serve as a
mechanism underlying metastatic dormancy to help tumor cell survival or escape
immune surveillance.
Although endothelial cell markers CD31 and CD34 were detected in
histological sections of uveal melanoma [48] and cutaneous melanoma [49], their
presence was not connected to tube-like structures and the origin of the
endothelial marker positive cells was not defined. Dudley’s group described a
CD31 positive cutaneous melanoma cell population that was also positive for the
melanocytic marker Tyr. These CD31+/Tyr+ VM-competent tumor cells existed
as stable, yet hidden subpopulations in heterogeneous melanomas [50]. The
population of CD31+ cells described in this study is different in that they
transitioned from expressing Tyr to expressing CD31 during the dissemination
process and reverted back to expressing Tyr upon successful metastasis
formation. VE-cadherin is a well-recognized marker for VM, GFP+ cells within the
primary tumors of Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice were positive
for VE-cadherin and maintained VE-cadherin expression during the metastatic
process. However, GFP+ cells lost VE-cadherin expression in the metastatic foci
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in the lung. Given the rich vasculature and gas exchange function of the lung
tissue, this result could be interpreted with the assumption that VM is not
necessary for the growth of metastases. Nonetheless, the internal or external
factors required for triggering the dynamic gene expression changes of
metastatic melanoma cells in Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice
are not clear. The study led by Kaessmeyer et al. demonstrated that the coculture of lung endothelial cells and squamous or adenocarcinoma lung cancer
cells resulted in a contact dependent “CD31 staining switch”, shown by the
acquisition of CD31 expression of the tumor cells in direct contact with
endothelial cells. This study suggested that tumor plasticity might be influenced
by the endothelial microenvironment and by direct interactions with endothelial
cells [51].
Endothelial-mesenchymal transition featured by the loss of endothelial
marker expression, such as CD31, with the concomitant increase in
mesenchymal marker expression, such as -SMA / VIMENTIN / FSP1, was
originally observed during heart development where a population of endocardial
cells differentiated into mesenchymal heart cushion cells forming cardiac septa
and valves [52]. Later on, this phenotypic transition was shown to contribute to
cardiac fibrosis [53] and carcinoma associated fibroblasts [54] in mouse models
[55]. Transforming growth factor-beta (TGF-) and bone morphogenetic protein
(BMP) family of growth factors are key players in EndMT [56, 57]. Generation of
mesenchymal cells from endothelium is a crucial step in the multipotent
differentiation of endothelial cells and acquisition of a stem-like phenotype was
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observed in endothelium during EndMT [57, 58]. The role of EndMT in cancer,
especially during metastasis, has only recently been recognized. Endothelialmesenchymal transition was observed in endoglin-deficient vasculature and this
process facilitated tumor cell intravasation in multiple mouse models [59]. The
observation that cancer cells can acquire an endothelial-like phenotype and be
incorporated into vessels suggested an extra role for EndMT in tumor
progression. Selek et al. proposed that through EndMT, endothelial-like cancer
cells can transdifferentiate into cancer associated fibroblasts or mesenchymal
cancer stem cells (MCCs), and that either one can contribute to tumor
progression. Additionally, disruption of tumor vasculature by antiangiogenic
therapies may result in the dissemination of MCCs responsible for latent
metastasis[31].
Despite of substantial evidence supporting the existence of tumor derived
endothelial cells and the role played by EndMT in tumor progression, a robust
connection between them and tumorigenesis is still missing, particularly in
melanoma. The results presented here showed that in vivo metastatic melanoma
cells can transdifferentiate into endothelial cells during metastasis and the
subsequent transition into a mesenchymal phenotype may contribute to latent
metastasis in the lung. We hope these findings will fill in the gaps in melanoma to
endothelial transition, and offer a possible new mechanism underlying melanoma
latent metastasis.

91

3.4 References
1.

Naumov, G.N., et al., Tumor-vascular interactions and tumor dormancy.
APMIS, 2008. 116(7-8): p. 569-85.

2.

Donnem, T., et al., Vessel co-option in primary human tumors and
metastases: an obstacle to effective anti-angiogenic treatment? Cancer
Med, 2013. 2(4): p. 427-36.

3.

Dome, B., et al., Vascularization of cutaneous melanoma involves vessel
co-option and has clinical significance. J Pathol, 2002. 197(3): p. 355-62.

4.

Leenders, W.P., et al., Antiangiogenic therapy of cerebral melanoma
metastases results in sustained tumor progression via vessel co-option.
Clin Cancer Res, 2004. 10(18 Pt 1): p. 6222-30.

5.

Bissell, M.J., Tumor plasticity allows vasculogenic mimicry, a novel form of
angiogenic switch. A rose by any other name? Am J Pathol, 1999. 155(3):
p. 675-9.

6.

Maniotis, A.J., et al., Vascular channel formation by human melanoma
cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol, 1999. 155(3):
p. 739-52.

7.

Hendrix, M.J., et al., Expression and functional significance of VEcadherin in aggressive human melanoma cells: role in vasculogenic
mimicry. Proc Natl Acad Sci U S A, 2001. 98(14): p. 8018-23.

8.

Delgado-Bellido, D., et al., Vasculogenic mimicry signaling revisited: focus
on non-vascular VE-cadherin. Mol Cancer, 2017. 16(1): p. 65.

9.

Sood, A.K., et al., Molecular determinants of ovarian cancer plasticity. Am
J Pathol, 2001. 158(4): p. 1279-88.

10.

Sharma, N., et al., Prostatic tumor cell plasticity involves cooperative
interactions of distinct phenotypic subpopulations: role in vasculogenic
mimicry. Prostate, 2002. 50(3): p. 189-201.

11.

Hendrix, M.J., et al., Molecular biology of breast cancer metastasis.
Molecular expression of vascular markers by aggressive breast cancer
cells. Breast Cancer Res, 2000. 2(6): p. 417-22.

12.

Yang, S., et al., Functional roles for PECAM-1 (CD31) and VE-cadherin
(CD144) in tube assembly and lumen formation in three-dimensional
collagen gels. Am J Pathol, 1999. 155(3): p. 887-95.

92

13.

Hendrix, M.J., et al., Vasculogenic mimicry and tumour-cell plasticity:
lessons from melanoma. Nat Rev Cancer, 2003. 3(6): p. 411-21.

14.

Valyi-Nagy, K., et al., Stem cell marker CD271 is expressed by
vasculogenic mimicry-forming uveal melanoma cells in three-dimensional
cultures. Mol Vis, 2012. 18: p. 588-92.

15.

Liu, T.J., et al., CD133+ cells with cancer stem cell characteristics
associates with vasculogenic mimicry in triple-negative breast cancer.
Oncogene, 2013. 32(5): p. 544-53.

16.

Zhang, Y., et al., Clinical significances and prognostic value of cancer
stem-like cells markers and vasculogenic mimicry in renal cell carcinoma.
J Surg Oncol, 2013. 108(6): p. 414-9.

17.

Liu, T., et al., USP44+ Cancer Stem Cell Subclones Contribute to Breast
Cancer Aggressiveness by Promoting Vasculogenic Mimicry. Mol Cancer
Ther, 2015. 14(9): p. 2121-31.

18.

Prieto-Vila, M., et al., iPSC-derived cancer stem cells provide a model of
tumor vasculature. Am J Cancer Res, 2016. 6(9): p. 1906-1921.

19.

Lai, C.Y., B.E. Schwartz, and M.Y. Hsu, CD133+ melanoma
subpopulations contribute to perivascular niche morphogenesis and
tumorigenicity through vasculogenic mimicry. Cancer Res, 2012. 72(19): p.
5111-8.

20.

Sun, B., et al., Vasculogenic mimicry is associated with poor survival in
patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int
J Oncol, 2004. 25(6): p. 1609-14.

21.

Sun, B., et al., Vasculogenic mimicry is associated with high tumor grade,
invasion and metastasis, and short survival in patients with hepatocellular
carcinoma. Oncol Rep, 2006. 16(4): p. 693-8.

22.

Wang, S.Y., et al., Vasculogenic mimicry is a prognostic factor for
postoperative survival in patients with glioblastoma. J Neurooncol, 2013.
112(3): p. 339-45.

23.

Wagenblast, E., et al., A model of breast cancer heterogeneity reveals
vascular mimicry as a driver of metastasis. Nature, 2015. 520(7547): p.
358-62.

24.

Chang, Y.S., et al., Mosaic blood vessels in tumors: frequency of cancer
cells in contact with flowing blood. Proc Natl Acad Sci U S A, 2000. 97(26):
p. 14608-13.

93

25.

Zhou, F., et al., Metronomic chemotherapy in combination with
antiangiogenic treatment induces mosaic vascular reduction and tumor
growth inhibition in hepatocellular carcinoma xenografts. J Cancer Res
Clin Oncol, 2012. 138(11): p. 1879-90.

26.

di Tomaso, E., et al., Mosaic tumor vessels: cellular basis and
ultrastructure of focal regions lacking endothelial cell markers. Cancer Res,
2005. 65(13): p. 5740-9.

27.

Jackson, D.G., et al., LYVE-1, the lymphatic system and tumor
lymphangiogenesis. Trends Immunol, 2001. 22(6): p. 317-21.

28.

Gordon, E.J., N.W. Gale, and N.L. Harvey, Expression of the hyaluronan
receptor LYVE-1 is not restricted to the lymphatic vasculature; LYVE-1 is
also expressed on embryonic blood vessels. Dev Dyn, 2008. 237(7): p.
1901-9.

29.

Favre, C.J., et al., Expression of genes involved in vascular development
and angiogenesis in endothelial cells of adult lung. Am J Physiol Heart
Circ Physiol, 2003. 285(5): p. H1917-38.

30.

Baluk, P. and D.M. McDonald, Markers for microscopic imaging of
lymphangiogenesis and angiogenesis. Ann N Y Acad Sci, 2008. 1131: p.
1-12.

31.

Selek, L., et al., Existence of tumor-derived endothelial cells suggests an
additional role for endothelial-to-mesenchymal transition in tumor
progression. Int J Cancer, 2011. 128(6): p. 1502-3.

32.

el-Sabban, M.E. and B.U. Pauli, Cytoplasmic dye transfer between
metastatic tumor cells and vascular endothelium. J Cell Biol, 1991. 115(5):
p. 1375-82.

33.

Pollmann, M.A., et al., Connexin 43 mediated gap junctional
communication enhances breast tumor cell diapedesis in culture. Breast
Cancer Res, 2005. 7(4): p. R522-34.

34.

Stoletov, K., et al., Role of connexins in metastatic breast cancer and
melanoma brain colonization. J Cell Sci, 2013. 126(Pt 4): p. 904-13.

35.

Sun, B., et al., Epithelial-to-endothelial transition and cancer stem cells:
two cornerstones of vasculogenic mimicry in malignant tumors.
Oncotarget, 2016.

36.

Streubel, B., et al., Lymphoma-specific genetic aberrations in
microvascular endothelial cells in B-cell lymphomas. N Engl J Med, 2004.
351(3): p. 250-9.

94

37.

Pezzolo, A., et al., Tumor origin of endothelial cells in human
neuroblastoma. J Clin Oncol, 2007. 25(4): p. 376-83.

38.

Zhao, Y., et al., Endothelial cell transdifferentiation of human glioma stem
progenitor cells in vitro. Brain Res Bull, 2010. 82(5-6): p. 308-12.

39.

Wang, R., et al., Glioblastoma stem-like cells give rise to tumour
endothelium. Nature, 2010. 468(7325): p. 829-33.

40.

Ricci-Vitiani, L., et al., Tumour vascularization via endothelial
differentiation of glioblastoma stem-like cells. Nature, 2010. 468(7325): p.
824-8.

41.

Chen, X., et al., A new mosaic pattern in glioma vascularization:
exogenous endothelial progenitor cells integrating into the vessels
containing tumor-derived endothelial cells. Oncotarget, 2014. 5(7): p.
1955-68.

42.

Shaifer, C.A., J. Huang, and P.C. Lin, Glioblastoma cells incorporate into
tumor vasculature and contribute to vascular radioresistance. Int J Cancer,
2010. 127(9): p. 2063-75.

43.

Marumoto, T., et al., Development of a novel mouse glioma model using
lentiviral vectors. Nat Med, 2009. 15(1): p. 110-6.

44.

Soda, Y., et al., Transdifferentiation of glioblastoma cells into vascular
endothelial cells. Proc Natl Acad Sci U S A, 2011. 108(11): p. 4274-80.

45.

Chen, L., et al., A model of cancer stem cells derived from mouse induced
pluripotent stem cells. PLoS One, 2012. 7(4): p. e33544.

46.

Chen, L., et al., Mouse induced pluripotent stem cell microenvironment
generates epithelial-mesenchymal transition in mouse Lewis lung cancer
cells. Am J Cancer Res, 2014. 4(1): p. 80-8.

47.

Matsuda, S., et al., Cancer stem cells maintain a hierarchy of
differentiation by creating their niche. Int J Cancer, 2014. 135(1): p. 27-36.

48.

Folberg, R. and A.J. Maniotis, Vasculogenic mimicry. APMIS, 2004.
112(7-8): p. 508-25.

49.

Pisacane, A.M., F. Picciotto, and M. Risio, CD31 and CD34 expression as
immunohistochemical markers of endothelial transdifferentiation in human
cutaneous melanoma. Cell Oncol, 2007. 29(1): p. 59-66.

50.

Dunleavey, J.M., et al., Vascular channels formed by subpopulations of
PECAM1+ melanoma cells. Nat Commun, 2014. 5: p. 5200.

95

51.

Kaessmeyer, S., et al., Lung cancer neovascularisation: Cellular and
molecular interaction between endothelial and lung cancer cells.
Immunobiology, 2014. 219(4): p. 308-14.

52.

Eisenberg, L.M. and R.R. Markwald, Molecular regulation of
atrioventricular valvuloseptal morphogenesis. Circ Res, 1995. 77(1): p. 1-6.

53.

Zeisberg, E.M., et al., Endothelial-to-mesenchymal transition contributes
to cardiac fibrosis. Nat Med, 2007. 13(8): p. 952-61.

54.

Zeisberg, E.M., et al., Discovery of endothelial to mesenchymal transition
as a source for carcinoma-associated fibroblasts. Cancer Res, 2007.
67(21): p. 10123-8.

55.

Lin, F., N. Wang, and T.C. Zhang, The role of endothelial-mesenchymal
transition in development and pathological process. IUBMB Life, 2012.
64(9): p. 717-23.

56.

Xiao, L. and A.C. Dudley, Fine-tuning vascular fate during endothelialmesenchymal transition. J Pathol, 2017. 241(1): p. 25-35.

57.

Medici, D. and R. Kalluri, Endothelial-mesenchymal transition and its
contribution to the emergence of stem cell phenotype. Semin Cancer Biol,
2012. 22(5-6): p. 379-84.

58.

Medici, D., et al., Conversion of vascular endothelial cells into multipotent
stem-like cells. Nat Med, 2010. 16(12): p. 1400-6.

59.

Anderberg, C., et al., Deficiency for endoglin in tumor vasculature
weakens the endothelial barrier to metastatic dissemination. J Exp Med,
2013. 210(3): p. 563-79.

96

Figure 3.1 GFP+ cells inside the pulmonary vasculature expressed endothelial cell markers.
Immunostaining on lung cryosections indicated the primary tumor derived GFP+ cells were positive for endothelial
cell specific markers CD31 (A-D) and VE-cadherin (E-H).
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Figure 3.2 Confocal and 3D reconstruction of blood vessels.
2-3mm segments of pulmonary artery, pulmonary vein and aorta were dissected and directly visualized under the
confocal microscope. GFP+ tumor cells were found within the endothelial layer of all three types of vessels. GFP+
cells exhibited different morphologies that corresponded to the type of blood vessel they were located.
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Figure 3.3 Whole mount staining and 3D confocal reconstruction of arteries
where GFP+ cells were found.
Top panel 3D reconstruction of the whole mount staining showed that GFP+ cells
integrated into the vascular endothelium and expressed CD31 and VE-cadherin
(top surface is the endothelium of the vasculature, bottom is the smooth muscle
cell layer negative for endothelial cell markers). Lower panel is one section from
the 3D reconstruction confirming GFP+ cells are positive for endothelial markers
CD31 and VE-cadherin.
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Figure 3.4 Plasticity of GFP+ cells from primary tumor sites to lung metastases.
GFP+ cells did not express endothelial cell marker CD31 in the primary tumors
(A, only endothelial cells in the blood vessels were CD31+) but were VE-cadherin
positive (D). GFP+ cells were positive for both CD31 and VE-cadherin in the lung
vasculature (B, E), but lost the endothelial cell markers in lung metastases (C, F).
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Figure 3.5 Endothelial cell mimicry in lymph nodes.
Primary tumor derived GPF+ cells in the lymph nodes expressed LYVE-1 inside lymphatic vessels (A) and CD31
inside the blood vessels (B) and were strongly associated with the vascular endothelium no matter which type of
vessels they were in. GFP+ cells lost the lymphatic endothelial marker LYVE-1 inside the lung metastatic foci (C).
Note, one GFP+ cell outside the metastatic foci in the lung was LYVE-1 positive (C, star), although we cannot
identify whether this is a lymphatic vessel or blood vessel.
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Figure 3.6 Immunostaining of VIMENTIN on lung cryosections.
VIMENTIN positive (arrowhead) and negative (arrow) GFP+ cells were identified
at various locations in the lung (A), 3D projection from confocal z-stack images
(B) confirmed that primary tumor derived GFP+ metastatic melanoma cells
expressed mesenchymal cell marker VIMENTIN. Green, GFP; red, VIMENTIN;
blue, DAPI.
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Figure 3.7 GFP+ metastatic tumor cell acquired mesenchymal marker -SMA
expression in the lung.
GFP+ cell (arrowhead) maintained endothelial cell marker CD31 and acquired
the expression of mesenchymal cell marker -SMA, indicating an intermediate
state of EndMT. A CD31+/-SMA+/ GFP- cell (arrow) in close proximity to the
GFP+ cell shows the same phenotype. It is possible that this is an authentic
vascular endothelial cell undergoing EndMT, or a metastatic cell that was not
labeled with GFP. Lower right picture shows a higher magnification of the boxed
area. Green, GFP; red, -SMA; blue, DAPI; magenta, CD31.
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Figure 3.8 -SMA and CD31 immunostaining on lung sections.
A cluster of GFP+ cells located at the alveolar capillary. Both CD31-/-SMA+
(arrow) and CD31+/-SMA+ (arrowhead) GFP+ cells were found. No cell with
strong CD31+/-SMA- immunoreactivity was found in this view. Green, GFP; red,
-SMA; blue, DAPI; gray, CD31.
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Figure 3.9 3D reconstruction of GFP+ cells located in the pulmonary artery.
3D reconstruction of GFP+ cells in lung cryosection showed three -SMA
negative GFP+ cells (arrowhead) wrapped around one -SMA positive smooth
muscle cell (arrow). GFP, green; red, -SMA; blue, DAPI.
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Figure 3.10 Plasticity of GFP+ cells associated with the lung vasculature.
Immunostaining on lung cryosections was performed. Intravascular GFP+ cells showed stem cell marker SOX2
and OCT4 immunoreactivity. A subpopulation of GFP+ cells expressed gap junction protein connexin43. Arrows
indicate the immunoreactive GFP+ cells.
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Figure 3.11 Plasticity and heterogeneity of melanoma metastatic cells in other
organs.
Immunostaining of various markers in spleen, kidney and lymph nodes from DctGrm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice. Primary tumor derived GFP+ cells
scattered in the spleen had undetectable VE-cadherin expression while GFP+
cells inside the metastatic foci in the spleen showed strong VE-cadherin
expression (A, top panel). In the kidneys, no detectable or weak signal was
detected on GFP+ cell (A, lower panel). S100 staining was performed on lymph
node cryosections where GFP+ cells were found. GFP+ cells associated with the
vascular endothelium or within the lumen were negative for S100 (B).
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4.

CONCLUSIONS AND FUTURE DIRECTIONS
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4.1 Conclusions
Melanoma is not the most common type of skin cancer, but it causes the
most deaths. It is notorious for the high propensity to metastasize and poor
response to therapies. Numerous questions remain unanswered regarding the
process of melanoma metastasis, which is partially due to the lack of proper
melanoma metastasis mouse models. The Dct-Grm1/ K5-Edn3 mice not only
spontaneously develop melanoma tumors on the ear, tail and dorsal skin, but
also show metastases in the lung, providing an ideal system to identify the
intrinsic tumor initiating capacity of specific cell subpopulations within an
unperturbed tumor environment.
Using Cre/loxp system, I was able to label the primary tumor resident Tyr
expressing cells with GFP and perform lineage tracing of the GFP+ cells during
metastasis in the Dct-Grm1/ K5-Edn3 mice. I showed that the primary tumorderived differentiated Tyr expressing cell subpopulation or their progeny
possessed metastasis-initiating capacity and exhibited phenotypic plasticity
during the metastatic process. The GFP+ metastatic melanoma cells could reach
the distant organs and seed metastases successfully. Numerous GFP+ cells
were detected inside the vasculature and established strong association with the
vascular endothelium in the organs where metastases were identified.
Interestingly, GFP+ cells lost the pigmentation as well as melanocytic lineage
markers upon contact with the vascular endothelium was established.
Vasculature-associated GFP+ cells did not express melanoma stem cell markers,

110

however, they mimicked vascular endothelial cells by expressing CD31 and VEcadherin. Three-dimensional reconstruction by confocal microscopy further
identified the endothelial cell mimicry of GFP+ cells. The phenomenon was also
observed in the lymphatic vessels of lymph nodes. The phenotypic plasticity of
metastatic GFP+ cells was also corroborated by the fact that GFP+ cells lost the
endothelial cell marker expression and resumed pigment production when
populating the metastatic foci. Furthermore, the morphology and distinct
phenotypic entities of GFP+ cells in different metastatic organs substantiated the
plasticity of metastatic melanoma cells.
GFP+ cells in the lung vasculature were found positive for mesenchymal
markers -SMA or VIMENTIN. Assuming that the intravascular GFP+ cells were
the potential metastasis-initiating cells in the lung of Dct-Grm1/ K5-Edn3/ TYRCreERT2/ mT/mG mice, I propose a two-step mechanism underlying melanoma
metastasis that involves melanoma-endothelial cell transition at the primary
tumor site and EndMT at the metastatic site. The proposed model based on the
experimental observations and implied suggestions for the process of melanoma
metastasis in the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mouse is
summarized in Figure 4.1.
In conclusion, I have provided direct evidence that a specific cell
subpopulation within the primary tumor possesses tumor initiating capacity in the
context of metastasis. Lineage tracing of the metastatic melanoma cells in vivo
indicated the phenotypic plasticity of cancer cells. My results will not only
enhance our understanding of melanoma metastasis, but also provide insights
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for the diagnostics and re-examination of melanoma patients aiming at the
detection of “vascular hidden” metastatic melanoma cells.
4.2 Future Directions
The heterogeneity of tumors including melanoma has been recognized for
decades addressing the varied tumor initiating capacities of cell subpopulations
within the same solid tumors [1]. Although the cancer stem cell model has been
proposed for melanoma [2], it remains controversial and several questions are
still unanswered. In this study, I have shown that the more differentiated Tyr
expressing cells or their progeny (GFP+) possessed metastasis-initiating
capacities and seeded successful metastases in various distant organs of the
Dct-Grm1/

K5-Edn3/ TYR-CreERT2/ mT/mG mice. However, the

exact

subpopulation of the primary tumor derived GFP+ cells that initiated the distant
metastasis is not clear. Considering this, it would be of great interest to isolate
the circulating GFP+ cells and the lung vasculature-associated GFP+ cells in the
Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice and characterize the
tumorigenic capacities of these two populations. High deformability of Sox2expressing melanoma cells grown in 3D soft fibrin gels has recently been shown
to facilitate the extravasation of metastatic cells [3]. Given the morphological
plasticity of metastatic GFP+ cells I observed in the established lineage tracing
system, it is worthwhile to test the mechanical stiffness of the two GFP+ cell
subpopulations. RNA-sequencing would be another approach to further identify
the mechanism underlying the distinct tumorigenic capacities, if any, between the
circulating GFP+ cells and the lung vasculature-associated GFP+ cells.
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I proposed the melanoma-endothelial cell transition as the first step for Tyr
expressing cells to successfully metastasize based on the finding that CD31+
GFP+ cells were identified inside the vasculature at the primary tumor site. Most
of the studies focusing on characterizing tumor derived endothelial cells have
been carried out in the context of glioma. Hypoxia has been suggested as a
promoter of glioma cell transdifferentiation [4, 5]. Although melanoma tumors
from the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice were suggested to
display hypoxic areas [6], I did not observe sufficient CD31+ GFP+ cells within
the primary tumor mass. One possibility to explain this finding is that it was very
difficult to detect single cells due to the extensive amount of pigmentation in the
tumor sections. However, alternative factors other than hypoxia may be the
trigger of melanoma to endothelial cell transdifferentiation. For example, lung
carcinoma cells co-cultured with human microvascular lung endothelial cells
became strongly positive for CD31 as a non-angiogenic process for blood supply
[7].

To characterize the potential effects of tumor-endothelial cell contact in

melanoma, it would be interesting to perform similar co-culture of human
microvascular lung endothelial cells with human melanoma cells. To better
replicate the context of my in vivo experiments, human melanoma cells
overexpressing Grm1 would be the ideal cells to employ.
Furthermore, in the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice,
primary tumor derived GFP+ cells associated with lung vasculature were not
proliferating or dying and the number of those intravascular cells far exceeded
the number of metastatic foci in the lung. The above observations imply the
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features of metastatic dormancy. The presence of lung infiltrates surrounding the
GFP+ cell-containing vessels raises the question of why GFP+ cells were found
embedded in the vascular endothelium. Suppression of the immune system in
Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice will allow us to identify whether
lymphocyte infiltrates are the main suppressor of extravasation or EndMT of
GFP+ cells. Alternatively, the immune response observed is possibly a general
phenomenon of metastasis, and the intravascular GFP+ cells are intrinsically
programmed for remaining in a dormant state and can only be re-awaken upon
exposure to as yet unidentified environmental factors. Further studies to
determine both the intrinsic and extrinsic cues underlying entry into and exit from
dormancy state would be very valuable.
Late recurrence has been observed in human melanoma patients [8],
indicating the presence of residual cancer cells that escape the detection of
available techniques. Based on my observations in the mouse model, it is highly
possible that metastatic melanoma cells cease to express most, if not all,
melanocytic features and masquerade themselves as other cell types and
become clinically invisible. Labeling of primary tumor cells is impossible in human
patients and the loss of pigmentation of the intravascular metastatic melanoma
cells challenges their detection in metastatic organs. Other than the genetic
tracing of tumor cells in mouse models, analysis of tumor specific chromosomal
alterations[9-11] was used to identify the tumor derived endothelial cells in
human samples. BRAF mutations are found in approximately 60% of somatic
melanoma cases [12]. An antibody against BRAF V600E, the mutated form of
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BRAF, is commercially available. One possible alternative for detecting these
“invisible” metastatic cells in human melanoma samples is to use immunostaining
or flow cytometry with Anti-BRAF V600E and endothelial cell specific markers. If
a population of double positive cells in the primary or metastasis melanoma
samples can in fact be revealed, current strategies for melanoma metastasis
diagnostics and metastasis-targeted therapies need to be enhanced taking the
existence of these cells into consideration.
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Figure 4.1 Diagram of melanoma metastasis in the Dct-Grm1/ K5-Edn3/ TYRCreERT2/ mT/mG mice.
Primary tumor resident Tyr expressing cells express VE-cadherin, indicating VM.
Metastatic Tyr expressing cells or their progeny (GFP+, green color cells in
diagram) enter the vasculature through extravasation or transdifferentiate into
CD31+ endothelial cells establishing associations with the vascular endothelium.
Intravascular GFP+ cells move towards the metastatic site as circulating tumor
cells (CTCs) or may roll over the vascular endothelium during endothelial mimicry.
EVMM was only observed in metastatic tumor at the primary tumor site, not
distant organs in the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice. In the
lung, intravascular GFP+ cells form metastases through extravasation and grow
using angiogenesis or vessel co-option. A subset of CD31+ GFP+ cells in smaller
pulmonary vessels went through EndMT, suggesting a potential mechanism for
the metastasis-initiating capability of vasculature-associated metastatic cells.
Intravascular growth of GFP+ cells in the pulmonary capillaries with subsequent
extravasation when intravascular micro-metastatic foci outgrow the vessels they
are in can be another source for metastases formation.
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MATERIALS AND METHODS
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Mice and Genotyping
The

K5-tTA;TRE-Edn3-lacZ (K5-Edn3, for simplicity) mice,

which

overexpress Edn3 under the keratinocyte promoter Keratin 5 resulting in a
hyperpigmentation phenotype due to the accumulation of melanocytes at the
dermal-epidermal junction, were generated in our laboratory[1]. The Tg(Grm1)
Epv (E) mice (Dct-Grm1, for simplicity, a gift from Dr. William Pavan, NIH)
[2]express the metabotropic glutamate receptor 1 under the regulation of the
melanocyte

specific

Dopachrome

tautomerase

promoter

and

develop

spontaneous melanocytic tumors on the ear and tail, but rarely metastasize. The
progeny from the K5-Edn3 mice and Dct-Grm1 mice mating carrying all
transgenes, Dct-Grm1/ K5-Edn3, were used in this study as a melanoma mouse
model. The Dct-Grm1/ K5-Edn3 mice not only spontaneously develop melanoma
on the ear, tail and dorsal skin, but also metastasize to the lung with 80%
penetrance.
To genetically label Tyrosinase expressing cells in the Dct-Grm1/ K5-Edn3
mice and establish an in vivo lineage tracing system, Cre/loxp system was used
in this study. TYR-CreERT2 mice are widely used for melanoma or melanocyte
related studies. These mice have expression of CreER T2 fusion protein directed
by mouse Tyr promoter/enhancer regions. When bred with mice containing loxpflanked sequences, tamoxifen/4HT-inducible Cre-mediated recombination results
in the deletion of the floxed sequences in the Tyr-expressing cells of the offspring.
For the Cre-reporter mice, the bifluorescent mice mT/mG [3] was selected due to
the following reasons. First, it not only labels cells after Cre-mediated
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recombination, but also labels non-recombined cells. Second, the double
fluorescent reporter genes in these mice simplify the visualization of recombined
and non-recombined cells without the addition of an exogenous enzymatic
substrate like β-Galactosidase used in LacZ reporter mice. Third, the membrane
targeted tdTomato and GFP fluorescent proteins in mT/mG mice allows the
labeling to be visualized at single cell resolution which is important for lineage
tracing. The Cre/loxp system in this study using TYR-CreERT2 and mT/mG mice
will be established through the mating of those two mouse strains resulting in the
offspring TYR-CreERT2/mT/mG mice.
The genotyping of the Dct-Grm1/K5-Edn3/TYR-CreERT2/mT/mG mice was
carried out by DNA extraction from a small piece of the tail using standard
procedures and followed by PCR using the appropriate primers (Table S2) for
each transgene ([1, 2], The Jackson Laboratory). Mice were housed in the
University Animal Care Facility at Florida International University. The animal
protocol was approved by the Committee on Animal Care and Use and Office of
Sponsored Research at Florida International University and all Institutional
Animal Care and Use Committee regulations were followed.
4HT Topical Painting on Tumors
Topical administration of 4HT was performed by preparing a 50mg/ml
solution of 4HT (Sigma, H6278) in DMSO and applying enough solution to wet
the tumors with a small paint brush. Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG
mice were monitored for tumor appearance on the tail and dorsum. As soon as
the first tumor appeared, we topically painted 4HT on the primary tumors twice a
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day for three consecutive days during 3~4 weeks to ensure the labeling of most
Tyr expressing cells within the primary tumors. Mice were monitored for primary
tumor growth until 30 weeks, unless euthanasia was necessary due to poor
health. As such, mice were euthanized at different times after the first painting
that varied from 2 weeks to 30 weeks. After euthanasia, tumor burdened mice
were examined for the presence of metastases in the lungs as well as other
organs under the dissecting microscope. Pigmented lesions in the lung ranged
from large macro-metastatic tumors (>1mm in diameter) to smaller pigmented
lesions that were clearly visible with the naked eye (pepper-like micrometastases) or much smaller micro-metastases that were only visible under a
dissecting microscope.
Immunofluorescence Staining
Harvested organs were fixed in 4% paraformaldehyde (PFA) overnight at
4° C and washed in 1X PBS. Organs were cryo-protected by sequential
immersion in 15% and 30% sucrose and then embedded with OCT. 10m
sections were obtained for immunofluorescence staining. Sections were
incubated in blocking buffer (10% normal serum, 0.3% Triton X-100, 1%BSA
power) at room temperature for 1 hour and followed by primary antibody
incubation at room temperature for 1 hour or at 4° C overnight. Primary
antibodies were diluted in dilution buffer (1% BSA, 1% normal serum, 0.3% Triton
X-100). Sections were thoroughly washed before incubation in secondary
antibodies for 1 hour at room temperature. Sections were mounted with
fluoroshield mounting medium with DAPI (Abcam, ab104139) and visualized on a
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Leica Leitz DMRB fluorescent microscope or Olympus Confocal BX61
microscope. For pigment bleaching on primary tumor sections, slides were
incubated in 10% H2O2 in PBS at room temperature for about 16 hours followed
by regular immunostaining. Where necessary, tissue GFP and tdTomato
fluorescence from the mT/mG allele were photobleached by treatment with 3%
H2O2 in methanol and illumination on a fluorescent light box for 4 hours to
overnight at 4°C. GFP signal was amplified by anti-GFP antibody if necessary.
Primary antibodies used: GFP (1:500, Aves Labs, GFP-1020), Ki67 (1:200,
Abcam, ab15580), Cleaved Caspase 3 (1:200, CST, 9664s), Rat CD31 (1:200,
eBioscience, 14-0311-82), Rabbit CD31 (1:200, Abcam, ab28364), CD45 (1:200,
Biolegend, 103101), CD3 (1:200, Novusbio, NB600-1441), P75 (1:200, Millipore,
ab1554), Nestin (1:50, Millipore, MAB353), SOX10 (1:50, Santa cruz, sc17342),
TYR/TRP1 (1:200, gift from Dr. Vincent Hearing), LYVE-1 (1:200, eBioscience,
14-0443-80), VE-cadherin (1:200, Abcam, ab33168), SOX2 (1:200, Abcam,
ab97959), OCT4 (1:200, Abcam, ab18976), Connexin43 (1:200, CST, 3512),
S100 (1:200, Sigma, S2644). Secondary antibodies used: anti-chicken 488
(1:500, Abcam, ab150169), anti-rabbit 594 (1:400, Invitrogen, A11012), antirabbit 647 (1:400, Abcam, ab150075), anti-rat 647 (1:400, Abcam, ab150159).
H&E Staining of Lung Cryosections
Cardiac perfusion with PBS was performed immediately after euthanasia.
After the PBS perfusion, lungs were infiltrated with OCT through the trachea by a
18G needle. Sections were subjected to H&E staining as follows: dH2O for 30
secs; Gill’s Hematoxylin 3 (VWR, 87001-924) for 5 mins; running tap water for 1
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min; Clarifier (VWR, 89237-218) for 15 secs; dH2O for 30 secs; Bluing Agent
(VWR, 95057-852) for 45 secs; dH2O for 30 secs; 95% ethanol for 15 secs;
Eosin (poly scientific R&D Crop, s2186) for 45 secs; 95% ethanol for 30 secs;
100% ethanol for 10 secs; Xylene for 15 secs; Xylene for 1 min; dry slides and
mount with cytoseal (xylene-based medium).
Counting of Ki67+ or Caspase 3+ Intravascular GFP+ Cells in the Lung
15 non-parallel lung cryosections per Dct-Grm1/ K5-Edn3/ TYR-CreERT2/
mT/mG mouse (n=3) were immunostained for Ki67 or Caspase 3 together with
GFP. Total intravascular GFP+ cells were counted for each mouse. Among the
intravascular GFP+ cells counted, double positive (Ki67+GFP+ or Caspase
3+GFP+) cells were counted. Total number of intravascular GFP+ cells varied
from 29 to 243 per mouse. Percentage of Ki67+ or Caspase 3+ intravascular
cells was obtained through double positive intravascular cells/total intravascular
GFP+ cells.
Timing of Metastatic Cell Dissemination
Adult Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice were separated
into three groups based on the stage of tumor development on the tail: 1) before
nevus stage, where no noticeable tumor or nevus was observed; 2) nevus stage,
where the lesion was less than 1mm in height; 3) tumor stage, where a clearly
detectable tumor had formed. 4-HT was topically applied to the nevus/tumor site
by a small painting brush twice a day for three consecutive days. For the before
nevus stage, 4-HT was applied to the tail of Dct-Grm1/ K5-Edn3/ TYR-CreERT2/
mT/mG mice that were 8-month-old yet without detectable tumor or nevus. The

124

proximal 3-4 cm of the tail where lesions generally develop was 4HT painted
twice a day for three consecutive days.
Whole Mount Confocal Imagining and Immunofluorescence Staining of
Blood Vessels
A small segment (2-3mm length) of pulmonary artery, pulmonary vein,
thoracic aorta or abdominal aorta was used for whole mount imaging or staining.
The vessel segments were dissected and fixed in fresh 4% PFA in PBS at 4C
overnight. For confocal imaging, the vessels were cut open and mounted flat on
glass slides with fluoroshield mounting medium with DAPI (Abcam, ab104139).
For immunofluorescence staining, vessels were cut open and washed in 1%
Triton X-100 in PBS for 40 minutes and blocked in 1% Triton X-100, 10% FBS in
PBS for 90 minutes at room temperature. Primary antibodies were diluted in
blocking buffer as described previously; vessels were incubated with primary
antibodies in 0.5mL PCR tube at 4C for 20 hours with shaking. After PBS
washing for 30 minutes twice, secondary antibodies were applied in blocking
buffer for 2 hours. Vessels were washed in PBS thoroughly and mounted with
fluoroshield mounting medium with DAPI. Z-stack images were taken from the
top layer (endothelial layer) to the bottom layer (smooth muscle layer) at a step
size 0.5 to 1m, 30 to 60 z-slice images were taken with Olympus Confocal BX61
microscope. 3D reconstruction or 3D projection of the z-stack images was
performed with Fiji-ImageJ software.
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Figure S 1. GFP+ cells in the tail tumors after 4HT induction.
Primary tumor cryosections 7 months after the first 4HT painting. 4HT topical
painting was performed once (twice a day for three consecutive days) when the
tail tumor was at the nevus stage. Few GFP+ cells were identified in the tumor
(A). 4HT topical painting was performed for 4 weeks since the nevus stage.
Numerous GFP+ cells were found in the tumor (B). Sections were counterstained
with DAPI (blue).
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Tag#
&Genotype

4HT Painting
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Painting
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Lung
Metastasis

#298*

tail tumor

2

#875*

tail tumor

5

#300*

tail tumor

5

#396*

3

#471*
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dorsal tumor
with 2-3 mm
in height
tail tumor
tail tumor

micrometastasis
micrometastasis
micrometastasis
micrometastasis

#365*

tail tumor
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tail & dorsal
tumor
tail & dorsal
tumor

tail
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dorsal 1

#443*

dorsal tumor

4

#476*

dorsal tumor

1

#451*
#479*

tail & dorsal
tumor
dorsal tumor

tail
3,
dorsal 5
10

#425*

tail tumor

8

#997*
#369*

Control (n=10)
Dct-Grm1/K5Edn3/mT/mG
Control (n=3)
Dct-Grm1/ K5Edn3/
TYRCreERT2/
mT/mG

dorsum
(before
nevus)

GFP+
Cells
in
Lung
no

GFP+
Cells in
Lymph
Nodes
no

GFP+
cells in
Other
Organs
NA

no

no

NA

yes

no

NA

yes

no

NA

no
micrometastasis
micrometastasis
micrometastasis

no
no

NA
yes

NA
NA

no

no

NA

yes

yes

NA

micrometastasis
pepper like
micrometastasis
no

yes

yes

NA

yes

yes

NA

yes

yes

NA

no

yes

NA

yes

NA

NA

yes

yes

spleen,
kidney

no

NA

1~8

micrometastasis
micrometastasis
macrometastasis
micrometastasis
yes

no

NA

NA

1

no

no

NA

NA

4
8

tail
1,
dorsal 5
tail
4,
dorsal 7
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Table S 1. 4HT induction of GFP expression and lung metastasis.
Macroscopic metastases in other organs were only observed in mouse#479, and
GFP+ cells were found in those organs. When macroscopic metastases were not
found, organs were not checked for GFP+ cells (NA), except brains (no GFP+
cells in any of the mice). Painting time “1” means 4HT topical application twice a
day for three consecutive days. Every painting was performed for a duration of
three or four weeks. All paintings started from nevus stage, unless specified, and
lasted until the mouse was euthanized. Painting of dorsal tumors may have
started post nevus stage because of the difficulty in detecting the nevi under the
coat. For genotype, “*” indicates Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG
experimental mice, genotypes of control mice were specified in table.

130

Figure S 2.Primary tumor derived GFP+ green cells were found in different
organs.
A-E, lung; F-G, spleen; H-I, kidney. Note, most of the green cells were single
cells with an elongated shape; clusters of cells were mostly confined to micrometastasis (D) or macro-metastasis (F, pigmented lesion in the spleen). Most
GFP+ cells found in the lung vasculature were in close association with the
vascular endothelium (A-C) with rare cases in the lumen of the vasculature
corresponding to the circulating cells (E). Scattered single GFP+ cells were
detected in the spleen (G), between the renal tubules (H) and adjacent to
glomeruli (I).
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Figure S 3. Cleaved Caspase 3 staining on the lung.
One GFP+ cell in contact with the pulmonary vascular endothelium was positive for Caspase 3, indicating this cell
underwent apoptosis.
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Figure S 4. Ki67 staining on lung perivascular infiltrates.
Most lymphocytes inside the infiltrates were Ki67 positive indicating the activation of immune response towards the
emergence of GFP+ cells inside the vessels.
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Figure S 5. Metastatic tumors on the skin.
4HT was applied to the dorsal tumor and distal tail tumor (arrowhead) of the DctGrm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mouse shown here. Proximal tail tumor
(boxed area) was mostly constituted by GFP+ cells indicating it was a metastasis
derived from the Tyr+ cells from the distal tail or dorsal tumor.
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Figure S 6. GFP+ cells inside the alveolar capillaries were CD31 positive.
Lung cryosections (A-H) depicting GFP +cells (A, E) inside alveolar capillaries, were labeled with CD31 antibody (B,
F) and counterstained with DAPI (C, D). Some GFP+ cells were CD31 positive (D, H, arrowhead) and some were
not (H, arrow) indicating the heterogeneity of metastatic tumor cells.
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Gene
TYRCreERT2

Sequence 5' --> 3'
CTC TGC TGC CTC CTG GCT TCT
CGA GGC GGA TCA CAA GCA ATA
TCA ATG GGC GGG GGT CGT T
mT/mG
GCG GTC TGG CAG TAA AAA CTA TC
GTG AAA CAG CAT TGC TGT CAC TT
CTA GGC CAC AGA ATT GAA AGA TCT
GTA GGT GGA AAT TCT AGC ATC ATC C
Dct-Grm1
CCGGGTCCGCATTAATCTTATCTA
GGTAGCATACGGTTCCACGCA
K5-Edn3
CCAGGTGGAGTCACAGGATT
ACAGAGACTGTGGACCACCC
GGCCTGTGCACACTTCTGT
TCCTTGTGAAACTGGAGCCT
Table S 2. Primers for mouse genotyping.
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